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Best practice clinical guidelines for myopia control involve an understanding of the
epidemiology of myopia, risk factors, visual environment interventions, and optical and
pharmacologic treatments, as well as skills to translate the risks and benefits of a given myopia
control treatment into lay language for both the patient and their parent or caregiver. This
report details evidence-based best practice management of the pre-, stable, and the
progressing myope, including risk factor identification, examination, selection of treatment
strategies, and guidelines for ongoing management. Practitioner considerations such as
informed consent, prescribing off-label treatment, and guides for patient and parent
communication are detailed. The future research directions of myopia interventions and
treatments are discussed, along with the provision of clinical references, resources, and
recommendations for continuing professional education in this growing area of clinical
practice.
Keywords: myopia control, myopia progression, clinical considerations, patient communica-
tion, practitioner education
1. IDENTIFYING THE MYOPIA MANAGEMENT PATIENT
1.1 Risk Factors
Myopia has been traditionally viewed as a consequence of
interplay between genetic, ethnic, and environmental risk
factors,1,2 and the important associations are detailed below.
1.1.1 Refractive Error and Eye Growth. In a normal eye,
the process of eye growth is regulated to proceed from
hypermetropia to emmetropia, rapidly within the first year of
life and then more slowly until emmetropia is achieved in mid
childhood.3 The process of emmetropization is designed to
match the increasing axial length of the eye with the focal
lengths (reducing power) of the cornea and crystalline lens.4
Although axial elongation during emmetropization occurs more
rapidly in younger (6–10 years) than older (12–16 years)
children,5 in myopia, this process is accelerated and overshoots
emmetropization.6 In a myopic eye, the fastest growth in axial
length appears to be the year before onset, with children who
become myopic showing significantly more axial elongation up
to 3 years before onset and through to 5 years after onset.7
With refractive error being the key clinical measurement,
lower hyperopia than age-normal can indicate risk of myopia
development; future myopes show less hyperopic refractions
for up to 4 years before onset of myopia compared with age-
matched counterparts who stayed emmetropic.7 In an ethni-
cally diverse, U.S.-based study that included more than 4500
children, first grade (age 6) children measuring þ0.75 diopters
(D) or less by cycloplegic refraction had increased risk of
becoming myopic between second and eighth grades (ages 8–
14 years) compared with those with þ0.75 D or greater
refraction, with the risk of myopia increasing with number of
myopic parents.8,9 Additional cutoff points for age-normal
hyperopia, below which myopia risk is significant, are
suggested to be þ0.50 D or less for ages 7 to 8 years, þ0.25 D
or less for ages 9 to 10 years, and emmetropia for age 11
years.10
1.1.2 Age. Myopia can be classified by age as childhood or
‘‘school’’ myopia6 and late onset (after 15 years of age).11,12 The
major factor contributing to faster childhood myopia progres-
sion is younger age at myopia onset, with this factor being
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independent of sex, ethnicity, school, time spent reading, and
parental myopia.13–15
1.1.3 Family History and Ethnicity. Myopia is heritable,
with the risk of developing myopia increased threefold or more
among children with two myopic parents compared with
children with no myopic parents.1,2,16,17 Additionally, ethnic
background also plays a role in myopia susceptibility. In
Australia, East Asian children aged 11 to 15 years are eight
times more likely to be myopic than their Caucasian
counterparts.18 In British children of a similar age, exposed
to the same schooling environment, those of South Asian
ethnicity had a 25% prevalence of myopia, followed by black
African Caribbeans at 10% and white Europeans at 4%.19
There is debate on whether childhood myopia is inherited
as a genetic susceptibility, influenced by the myopigenic
environment created by myopic parents, or both. Children of
myopic parents have been shown to spend less time outdoors
and more time reading than children of emmetropic parents,20
both of which are associated with myopia onset and
progression.
1.1.4 Visual Environment. Although there is a genetic
component in myopia development, the visual environment
appears to be a major contributor to school-aged myopia.6
Children who become myopic appear to spend less time
outdoors compared with their nonmyopic counterparts.21
Additionally, the risk of myopia development and progression
is significantly associated with reading at very close distances
(<20 cm) and for continuous periods of time (>45 minutes)
rather than being associated with total time spent on all near
activities.22,23 These factors may be related to short-term
changes in central axial length that have been shown to occur
in progressing and higher (early-onset) young adult myopes
after both short-term, high (6 D) demand24 and prolonged,
standard working distance (3 D) near work demand.25 The
balance between less time spent outdoors and more time spent
on near work has yet to be comprehensively defined.
It is not clear whether the beneficial effect of time spent
outdoors is due to the brightness of light exposure,26,27
increased short-wavelength (360–400 nm) and UV light
exposure,28,29 the more uniform dioptric field of view across
the retina when outdoors compared with indoor environ-
ments,30 or other mechanisms. Although increased time spent
outdoors is effective in attenuating the onset of myopia, there
is little evidence that outdoor time regulates progression of
existing myopes, as measured by refraction.21 More detail on
visual environment interventions can be found in the IMI –
Interventions for Controlling Myopia Onset and Progression
Report.
1.1.5 Educational Activities. A much higher prevalence of
myopia has been reported among many Asian and South East
Asian countries; a commonality between these countries is the
focus on academic achievement and an intense education
system.31,32 Examples include test driven, highly competitive
education systems in Asia and Asian communities33–35 and the
high prevalence of myopia in Orthodox Jewish boys compared
with girls in Jerusalem, where the boys spend much more time
reading religious texts at close working distances.36
A number of reports have indicated that a school
curriculum consisting of greater near work demands is
associated with a higher rate of myopia36,37 and a faster rate
of myopia progression.38 There have also been suggestions that
extensive engagement in afterschool tutorials may impose
additional workload to the school children and is associated
with a high prevalence rate of myopia.39 Mendelian random-
ization analyses have shown that every additional year of
education is associated with a more myopic refractive error of
0.27 D.40
Individuals with a high genetic risk and university-level
education had a higher risk of myopia than those with a high
genetic risk and only primary-level schooling. The combined
effect of genetic predisposition and education on the risk of
myopia appears to be substantially higher than the sum of
these two effects.40,41
1.1.6 Binocular Vision. There is a reported association
between higher levels of esophoria and accommodative lag at
near in myopic children and young adults compared with
emmetropes.42–45 Myopic children and young adults also show
reduced accommodative facility45,46 and enhanced accommo-
dative convergence (elevated accommodative convergence to
accommodation [AC/A] ratios) compared with age-matched
emmetropes.47-49 Conjecture exists, however, as to whether
accommodative errors are a feature rather than a cause of
myopia: some studies show a higher accommodative lag
associated with myopia progression in children and adults,45,50
whereas others do not.51–53
1.2 Identifying and Managing the Premyope
The child at risk of developing myopia can be identified by
comparing their refractive error to the age-normal as detailed
in Section 1.1. Having one or two myopic parents increases
risk, along with less time spent outdoors and more time spent
reading.27,54,55 The premyope may also show specific binoc-
ular vision disorders (see Section 4.3 for more detail), including
reduced accommodative responses, increased accommodative
lag, and higher AC/A ratios.56 The effect of managing these
disorders on myopia development has not yet been defined.
Recommending an increase in time spent outdoors is the key
evidence-based strategy that appears effective in reducing the
incidence of myopia across numerous studies.21
2. DISCUSSING MYOPIA AND ASSOCIATED RISKS WITH
PARENT AND PATIENT
2.1 Lay Terminology Discussion of Causes
Patients and parents must be informed on the probable causes
and risk factors for myopia to enable them to understand their
child’s risk profile and reduce their exposure to avoidable risk
(see Section 1). Written lay education is important to
consolidate in-office verbal education and serves as a reference
between visits.
As children with parental myopia are more likely to develop
myopia than those without, and those with parents with high
myopia are at risk of developing myopia earlier than their peers
and becoming more myopic than children of nonmyopic
parents, it is important to discuss a child’s risk for myopia
development and/or progression with the parents and/or
caregivers.
Despite the undeniable and unavoidable influence of
heritability and ethnicity, it has been established that eye
growth is significantly influenced by the visual environment.
Therefore, it is important that these risk factors are discussed
to encourage healthy visual habits, such as spending more time
outdoors and reducing near work demand, to delay myopia
onset or reduce myopia progression.
2.2 Lay Terminology Discussion of Eye Health Risk
Discussions of the risks and consequences of myopia should
take place with parents of children at risk of developing
myopia (see Section 1.2), as well as children who are already
myopic, with emphasis on the latter. Myopic eyes typically
demonstrate excessive axial elongation and structural changes,
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making them more at risk of developing retinal holes, tears or
detachments, myopic maculopathy, glaucoma, and cataract.30
The higher the myopia and the longer axial length becomes,
the higher the lifetime risk of developing these comorbiti-
ties.30,57 It is therefore vital that patients and parents are made
aware of the potential risks associated with being myopic.
Written lay education and online risk calculators have an
important role in complementing in-office verbal education to
encourage behaviours that could reduce myopia onset and
progression (see Sections 3, 5, and 6). Patient and parent
education regarding all evidence-based treatment options is
important in aiding decision making, when taken in view of
practitioner prescribing based on examination findings. For
more detail on the evidence of specific treatment types, see
the IMI – Interventions for Controlling Myopia Onset and
Progression Report.
3. MYOPIA CONTROL TREATMENTS: RISKS, BENEFITS,
AND EXPECTATIONS
3.1 Lay Terminology Discussion of Options
It is important to educate patients and parents on the evidence-
based treatment options available (see Sections 4 and 5 for
identifying treatments based on examination findings). Written
material is beneficial to support in-office verbal education.
Examples of evidence-based education by treatment modality
are provided below and can be adapted based on availability of
these treatments to the practitioner and the individual. Detail
on the scientific evidence supporting various myopia control
treatment options can be found in the IMI – Interventions for
Controlling Myopia Onset and Progression Report.
Examples of parent- and patient-appropriate explanations of
myopia control options are as follows. Orthokeratology (OK)
lenses are rigid gas permeable contact lenses worn overnight
to reduce nearsightedness by temporarily and reversibly
reshaping the cornea (front surface of the eye).58 Multifocal
soft contact lenses (MFSCLs) have two or more powers in them
and were originally designed to correct both far vision and
near/intermediate vision in adults. Both contact lens treat-
ments are thought to slow the progression of nearsightedness
in children by focusing light at the periphery of the eye in
alignment or in front of the retina.59 Atropine is a prescription
eye drop used to temporarily dilate (open) the pupil and limit
the ability to accommodate (focus). It is thought to slow the
progression of nearsightedness through interaction with some
of the receptors in the eye that control eye growth.60
3.2 Lay Terminology Discussion of Efficacy and
Additional Correction Benefits
Parents should be provided information on expected efficacy
and other potential benefits of myopia control treatments.
Detail on efficacy of the myopia control treatment options can
be found in the IMI – Interventions for Controlling Myopia
Onset and Progression Report. Furthermore, discussion of the
responsibility of presenting this information to the public to
avoid bias is provided in the IMI – Industry Guidelines and
Ethical Considerations for Myopia Control Report. Examples of
evidence-based education in lay language are provided below.
Note that references compare myopia control treatment to
traditional single vision spectacle or contact lens correction.
No current myopia control treatment can permanently stop
or reverse the progression of nearsightedness, although
cessation of progression is sometimes observed in clinical
practice. Generally, nearsighted children wearing traditional
single vision glasses or contact lenses will continue to increase
in nearsightedness by approximately 0.50 to 1.00 D (units of
measurement) per year, as accelerated eye growth occurs.61
The myopia control treatments discussed below are expected
to slow the rate of progression; which means the average child
would still have some progression in nearsightedness. Mea-
surements of the child’s prescription and the length of the eye
can provide more information about the effectiveness of
various treatments. The myopia control treatment effect for an
individual child may be higher or lower than the average and is
based on numerous factors, and the long-term effectiveness is
not fully understood as the available data only extend to 1 to 5
years of treatment.
OK lenses are expected to slow myopia progression by
approximately 30% to 60%.62–65 Additional benefits include not
having to wear a vision correction during the day. Some
parents also like that they can oversee contact lens wear since
lenses are only worn at night.
MFSCL are expected to slow myopia progression by about
30% to 50%, although studies have investigated several
different lens designs, some of which have shown higher
results.66–70 This correction also allows part-time wear, but this
may reduce the myopia control effect.67
Children wearing soft contact lenses have been shown to
have improvements in self-perception and self-esteem com-
pared with children wearing glasses.71 Although not studied, it
is expected that similar improvements would be found with
OK contact lenses because these children do not need to wear
glasses during waking hours, where full myopia correction has
been achieved.
Atropine eye drops can be expected to slow myopia
progression by approximately 30% to 80%, although significant
adverse effects (light sensitivity and reduced near vision) can
occur with stronger dosages.72–74 Lower strength doses (i.e.,
0.01%) may have less side effects but may not be as effective as
higher strengths (i.e., 0.5% and 1.0%),73 although rebound
effects—accelerated myopia progression—after cessation of
higher strength atropine treatment have been found.74 It is also
important to note that despite effects on slowing the level of
myopia, the effect of low dose (0.01%) atropine on slowing eye
growth has not been convincingly established.75
Specific spectacle lens options can also provide treatment
effects for some children of approximately 20% to 50%, in
specific populations.76,77
3.3 Lay Terminology Discussion of Safety and
Other Risks and Challenges
Finally, parents should be informed of potential risks and side
effects associated with myopia control treatments. Examples of
lay education on general risks are provided below, and
education on how to minimize risks is provided in Section 6.
To date, no studies have examined children using myopia
control treatments for more than 5 years, and not all the
studies reported safety information, but data from clinical trials
and record reviews do provide information on the major risks
associated with myopia control treatments.
The most significant risk associated with contact lenses is
microbial keratitis (a bacterial infection of the clear front of the
eye called the cornea), which in a small percentage of cases
can result in vision impairment. The rate of new cases of
microbial keratitis in children wearing overnight OK lenses is
13 in 10,000 per year.78 For soft contact lenses, the rate of
corneal infiltrative events is about 15 per 10,000 per year for
children age 13 to 17 years.79 The rate of microbial keratitis for
children 8 to 12 years of age wearing soft contact lenses
appears to be less than that of adults or teenagers, but cannot
be accurately estimated with the data available.79,80
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Other risks associated with the use of contact lenses
include other types of infections or inflammation (swelling) or
abrasions (scratches) of the eye. Most of these complications
do not result in any long-term damage to the eye.
Compared with glasses, children may notice mildly blurred
vision or changes in their focusing with either OK or
MFSCLs.81,82
The most common side effects associated with the use of
atropine eye drops are a temporary stinging or burning,
blurred vision, and sensitivity to lights.83 Lower strength doses
may cause less of these side effects.73,84
Although generally showing lower efficacy than other
options,85 the risks of side effects with spectacle lens
corrections is minimal.
3.4 Informed Consent and Prescribing Off-Label
Treatments
Despite being widely accepted as evidence based, currently
available treatment options for myopia control are yet to be
approved by the US Food and Drug Administration (FDA) so
their use must be considered ‘‘off-label.’’ At the time of writing,
two daily disposable MFSCLs (Coopervision Misight and
Visioneering Technologies NaturalVue) had received approval
from EU regulatory authories CE marking (certification
standard) for myopia control, which is recognized in Europe,
Australia, New Zealand, Canada, and parts of Asia and is
independent of FDA approval. Further information on the
relevance of off-label treatments, lack of FDA approval, or
presence of CE marking in particular countries is provided
below—the practitioner should also seek specific advice from
their representative organizations in their country where
required.
Due to this complex regulatory environment and the
involvement of children as patients, providing proper informed
consent is an important part of myopia management. Full
disclosure to parents/carers and patients on myopia control
treatment efficacy, risks and benefits, and off-label use (where
relevant) should be included. The informed consent form used
by the University of California Berkeley Myopia Control Clinic
is provided in the Supplementary Material as an example—
note that spectacle lens options are not included in this
instance. For more detail on the ethical considerations of
practitioners in prescribing for myopia control—including
regulatory advice on off-label prescribing, consent forms, and
avoiding bias in information provided to parents and patients—
refer to the IMI – Industry Guidelines and Ethical Consider-
ations for Myopia Control Report.
The practitioner should be aware of regulatory and
professional requirements regarding use of off-label treatments
in their country of practice. The definition and legality of use of
off-label treatment varies significantly across the world, and the
practitioner should ensure they understand the legislative,
regulatory, and professional aspects of off-label prescribing in
their country. For example, in the United States, off-label
treatment is defined as ‘‘FDA-approved drugs/medical devices
used for nonapproved indications,’’ which is considered legal
as long as there is sufficient evidence supporting the efficacy
and safety in such application.86
In the United Kingdom, optometrists with ‘‘additional
supply’’ or independent prescribing qualifications are able to
use and supply 0.5% and 1.0% doses of atropine for indications
involving temporary cycloplegia or mydriasis. The use of lower
doses (i.e., 0.01%) for myopia control is not currently listed on
the Optometrists’ Formulary87; therefore, further advice from
professional organizations may be prudent.
The European Union legislation ‘‘does not regulate the way
medicinal products are ultimately used in medical practice.
The prescribing of a medicinal product, on-label or off-label, is
a decision taken within the relationship between a patient and
his or her treating healthcare professional (HCP). The way
Member States organize their healthcare system and the way
HCPs conduct their practice is not a topic that falls within the
remit of the EU.’’88
In Australia, according to the National Prescribing Service
(NPS), off-label prescribing is ‘‘unavoidable and very common,
especially if your practice includes children.’’ Off-label
prescribing means that the Therapeutic Goods Administration
(TGA) has not approved the indication, route of administration,
or patient group. It does not mean that the TGA has rejected
the indication. Commonly the TGA has not been asked to
evaluate the indication. There is no legal impediment to
prescribing off-label; however, the onus is on the prescriber to
defend their prescription for an indication that is not listed in
the product information. If, in the opinion of the prescriber,
the off-label prescription can be supported by reasonable
quality evidence, for example, the indication is identified in the
Australian Medicines Handbook, the prescriber should proceed
if this is in the patient’s best interests. It is best if your patient
knows that their prescription is off-label and why you are
recommending the drug. Making a note of this ‘‘conversation’’
in the patient’s records and possibly even recording that the
patient ‘‘consented’’ would be good practice.89 Similar advice
is provided for New Zealand practitioners,90 with comparable
legislation or advice existing for optometrists in Hong Kong
and Canada—with the exception of Coopervision’s Misight
lens, which has received a myopia control indication from
Health Canada.91 In China, only certain products can be
prescribed by practitioners with specific licenses—more detail
can be found in the IMI – Industry Guidelines and Ethical
Considerations for Myopia Control Report.
4. KEY ELEMENTS OF THE BASELINE EXAM FOR
MYOPIA CONTROL
4.1 Standard Procedure for Examination
The following summarizes the standard procedures for
examination of myopes:
1. History taking: age, sex, history of ocular and general
health, ocular surgery, ocular and general health parental
history of myopia, age of onset of myopia, history of
myopia progression (if available), previous myopia
control treatments if any.
2. Refraction: noncycloplegic and/or cycloplegic refraction
as indicated. The IMI – Defining and Classifying Myopia
Report defines myopia by refraction ‘‘when ocular
accommodation is relaxed. These definitions avoid the
requirement for objective refraction so as to be
independent of technique, but by making reference to
relaxation of accommodation are compatible with both
cycloplegic and standard clinical subjective techniques.’’
If used, the recommended dosage for cycloplegic
refraction is two drops of 1% tropicamide or cyclopen-
tolate given 5 minutes apart. Cycloplegic refraction
should be performed 30 to 45 minutes after the first drop
is instilled.92 For more information on specific refraction
techniques that have been used in myopia control
studies, refer to the IMI – Clinical Myopia Control Trials
and Instrumentation Report.
3. Best-corrected visual acuity.
4. Binocular vision and accommodative tests: see Section
4.3.
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5. Anterior eye health evaluation using a slit-lamp and
intraocular pressure measurement.
6. Corneal topography: if indicated (for example, for
contact lens fitting).
7. Axial length (AL): although routinely employed in
myopia control studies to determine the outcome of
reduced axial elongation, measurement of AL is not
widespread in clinical practice, and at this point, there
are no established criteria for normal or accelerated axial
elongation in a given individual. It is well known that
during emmetropization, axial elongation is more rapid
in younger (6–10 years) than older (12–16 years)
children.5 However, there is a broad range observable,
with emmetropes typically showing an AL of 22 to 24.5
mm, and myopia typically associated with ALs greater
than 25 mm.57 Increases of about 0.1 mm/yr have been
shown to be associated with normal eye growth,
whereas 0.2 to 0.3 mm/yr is associated with increasing
myopia,7 although myopia progression can occur with
smaller AL changes in an individual. This makes AL
measurement currently an uncertain diagnostic factor in
clinical myopia management, but a useful factor in risk of
myopia pathology, where an AL approaching 26 mm in a
myopic child, where further axial growth is still
expected due to emmetropization, could increase the
index of concern for the practitioner.57
Where available, measurement with a noncontact device, for
example, IOL Master (Zeiss, Oberkochen, Germany) or
LENSTAR (Haag-Streit, Ko¨niz, Switzerland) is ideal. The mean
and SD of multiple measurements should be recorded.
1. Fundus examination and imaging: examination of both
the central and peripheral retina under dilation, annually
in high myopes and in others as indicated. If retinal
findings are noted, Optical Coherence Tomography
(OCT) images and/or fundus photos may be taken to
objectively document retinal features and/or abnormal-
ities. Practitioners may also grade and scale any retinal
changes in fundus photos (e.g., chorioretinal atrophy,
staphyloma, peripapillary atrophy, titled disc).93 More
detail on macular and nonmacular structural complica-
tions of myopia, including the Meta-analysis for Patho-
logical Myopia (META-PM) classification system for
myopic maculopathy, can be found in the IMI – Defining
and Classifying Myopia Report.
4.2 Visual Habits and Environment Evaluation
Given the association between near work and outdoor time to
myopia, it is preferred to obtain and record the visual habits of
the individual such as information about daily average hours of
time spent on near work and time spent outdoors.
4.3 Binocular Vision Evaluation
Assessment of binocular vision involves evaluation of both the
accommodative and vergence systems.94–96 The two primary
tests of accommodation are accommodative accuracy, clinically
measured as lead or lag of accommodation, and accommoda-
tive amplitude or the maximum accommodative ability (Table
1). In addition, accommodative facility is often measured to
assess an individual’s ability to adapt to rapid changes in
accommodation (Table 1). Accommodation can be assessed
under monocular (response driven by blur and proximal
stimuli) or binocular conditions (response to blur, proximal
and convergent stimuli). Tests adopted to assess the vergence
system include those evaluating the accuracy of fixation in
associated and dissociated conditions (Table 2). Heterophoria
is a misalignment of the eyes during the absence of fusion
(partial dissociation), whereas fixation disparity is misalign-
ment of the eyes during fusion.96 The primary evaluation of the
interaction of the accommodative and vergence systems is
accommodative convergence over accommodation ratio (AC/
A; Table 2), which is a measure of the convergence per diopter
change in accommodation.
Currently, there is no consensus on the gold standard
techniques for assessing binocular vision function, and various
methods have been used in clinical studies of myopia and
myopia control as outlined in Tables 1 and 2. It is
recommended that the baseline examination for myopia
control should include, as a minimum, tests that assess the
various elements of accommodation and vergence as listed in
Tables 1 and 2. Furthermore, the same tests need to be used in
follow-up consultations to monitor for changes. Previous
studies have suggested that not only atropine, but MFSCL and
OK can affect pediatric accommodative and binocular func-
tion.81,97
4.4 Dry Eye Evaluation
In myopic eyes, symptoms of dry eye–related disorders can
surface or be exarcebated in response to myopia control
treatments or exposure to environmental risk factors. These
are detailed below. It is therefore advisable that practitioners
monitor the ocular surface in children with myopia, as well in
those undergoing myopia control treatments.
Contact lens wear has been associated with dry eye, either
as a contributing factor to dry eye118,119 or because contact
lens discomfort and drop out is largely linked to dry eye.120–124
TABLE 1. Accommodative Function Tests Used in Clinical Studies
Accommodative
Assessment Clinical Tests
Accommodative accuracy
(lag or lead)
Open-field autorefractors (Canon R-
1,56,77,98–102 Grand Seiko WV-
500,13,52,66,103,104 or Grand Seiko WR-
5100105,106
Aberrometers (Complete Ophthalmic
Analysis System [COAS]
aberrometer107,108)
Monocular estimate method (MEM)
retinoscopy82,109,110
Nott dynamic retinoscopy111,112
Photorefractor113,114
Accommodative amplitude Minus lens technique (or Sheard’s
technique)109
Push up (or in) test66,114
Accommodative facility Distance (plano/2.00 D flippers)13,115
Near (62.00 D flippers)13,109,110,114,115
TABLE 2. Vergence Function Tests Used in Clinical Studies
Vergence
Assessment Clinical Tests
Distance and near
heterophorias
Risley prism and Maddox rod56
Von Graefe method116,108
Alternating cover test69,82,100,101,103
Howell near phoria card104,110
Saladin near point balance card81
Near fixation disparity Saladin near point balance card69,108
AC/A ratio Calculated method56,101,102,117
Gradient technique13,116,117
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Thus, the ocular surface should be regularly evaluated in an
individual wearing contact lenses.
Atropine in low doses for myopia control is often limited to
compounded formulations, often preserved with benzalko-
nium chloride (BAK). BAK has been shown to be toxic to the
corneal epithelium, is implicated in dry eye particularly with
long-term use as in glaucoma therapy, and may have toxic
effects in the retina.125,126 In addition to the suggestion that an
upper limit of 2 years of atropine treatment is recommended
for children,127 long-term use of eye drops with BAK may pose
an unacceptable risk of corneal toxicity and dry eye.
With evidence mounting that dry eye affects younger
populations119,128 potentially exacerbated by digital device
use,129–132 practitioners should consider a dry eye evaluation at
the baseline myopia control examination and monitor for dry
eye and meibomian gland dysfunction (MGD). Training
children in proper contact lens use, and avoiding preserved
eye drops or lens cleaning solutions by fitting daily disposable
contact lenses, may help to reduce the impact of myopia
control treatment on the ocular surface. For detail on dry eye
evaluation and treatment, refer to the Dry Eye Workshop
(DEWS II) series of reports, published in 2017.133
4.5 Exploratory Tests
4.5.1 Relative Peripheral Refraction (Uncorrected
Eye). The relation between peripheral refraction and refractive
errors in humans has been studied for nearly 50 years.
Hoogerheide evaluated 375 pilots and suggested that relative
peripheral hyperopia in the horizontal meridian could be a risk
factor for myopia development.134 Several cross-sectional
studies similarly illustrated an association between relative
peripheral hyperopia and central refraction, where greater
relative peripheral hyperopia was found in myopia, with
relative peripheral myopia found in hyperopes and emme-
tropes.135–137 There is conjecture, however, as to whether this
peripheral refraction pattern is more a consequence rather
than a cause of myopia development and whether it could be
used to predict a future myope or not.138,139
MFSCLs that are based on generating peripheral myopic
defocus have been shown to reduce myopia progression,68 and
similarly, OK has been shown to alter peripheral refraction
from relative hyperopia to myopia,140,141 consistent up to 1
year of wear.142 There is no clear evidence yet, however,
linking changes to peripheral refraction induced by MFSCL or
OK to myopia control or progression, so more understanding
of this proposed mechanism is required.
Peripheral refraction can be measured with an open field
autorefractor with targets positioned in the nasal and temporal
visual field across the horizontal meridian. This can also be
measured during MFSCL wear or in OK wear after the initial
fitting process has been completed. As research continues,
measuring peripheral refraction may be a clinical test used in
future.
4.5.2 Higher-Order Aberrations. It appears that there
may be some relationship between higher-order aberrations
and myopia control, but this is yet to be fully understood, and
use of aberrometers in clinical practice is uncommon. Higher
levels of total corneal higher order aberrations induced with
OK wear appear to be associated with a slower progression of
myopia and a smaller axial elongation. A significant shift in
positive spherical aberration appears to be a key correlation,143
whereas increased coma after OK treatment has been shown
not to be associated with its myopia control effect.144
4.5.3 Pupil Size. Based on available data, it is difficult to
ascertain the contribution of pupil size to myopia control. A
single study reported that pupil size is related to myopia
progression in OK treatment, where children with an ‘‘above
average’’ scotopic pupil diameter, defined as greater than 6.4
mm by the group mean, exhibited a greater myopia control
effect than children with a ‘‘below average’’ scotopic pupil
diameter.145 Within normal refractive development, however,
there is no consistent link between pupil size and myopia
progression. Further studies are needed to explore a potential
relationship between pupil size and myopia control efficacy.
4.5.4 Subfoveal Choroidal Thickness. A number of
studies have reported an association between choroidal
thickness changes and myopia progression,146 induced myopic
and hyperopic defocus,147 and myopia control intervention.148
Ongoing research is aimed at exploring the relationship
between myopia onset and progression with subfoveal
choroidal thickness (SFCT) at the macular region and in other
areas of the retina.
4.5.5 Wearable Devices to Track Visual Habits and
Environment. The association between development of
myopia and increased time spent in near work, or prevention
by increased time outdoors, has been largely determined by
questionnaire.54,149–153 More recently, light data loggers (LDLs)
have been used to make objective measures of ambient light
levels, including the HOBO Pendant (Onset Computer
Corporation, Bourne, MA, USA),154–156 and Actiwatch 2
(Philips Respironics, Murrysville, PA, USA).27,157,158 A cutoff
measure of 1000 lux has been suggested to differentiate indoor
and outdoor environments based on diary records,154,155,158
although there is some conjecture.159,160 Objective measures
of light intensity continue to show an association between
time spent outdoors and protection from myopia.155,161 In
addition, current generation wearable devices are also able to
determine the working distance at near and posture and could
shed further light on the impact of visual habits on onset and
progression of myopia.
5. SELECTING A TREATMENT STRATEGY
5.1 Predicting Progression Rate
In attempting to control progression of myopia, an under-
standing or estimation of the rate at which myopia progresses
for a given individual may help identify an appropriate strategy
to control the rate of progression. In this respect, it is
recognized that myopia will progress at a faster rate in those
that are of younger age,162 have higher baseline myopia,163 and
have experienced past myopia progression of >0.50 D/yr.164
Myopia can also progress more over winter than summer
seasons.165 However, although it may be possible to determine
the risk of progression, determination of the rate of progres-
sion in an individual is difficult as it can be influenced by a
multitude of other factors.
While acknowledging these individual variations, it still is
reasonable to estimate likely progression based on average
population-based progression rates. Donovan et al.61 conduct-
ed a meta-analysis of data of single vision distance spectacle-
corrected children who participated as control groups from 20
myopia control studies. Based on the meta-analysis, annualized
progression rates for myopic children of Asian and Caucasian
ethnicities ranged from about 0.50 to 1.00 D and varied by age
and sex. These data were used in the development of the Brien
Holden Vision Institute myopia calculator, which predicts level
of myopia at age 17 years based on inputs of a child’s current
age and level of myopia, if a single vision treatment was used,
and then illustrates the impact of various treatment strategies
on myopia progression (https://calculator.brienholdenvision.
org, in the public domain). Given that the calculator estimates
long-term progression based on study data of only 2-year
duration, parents should be cautioned that the calculator is for
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illustrative purposes and that the child’s actual myopia
progression and myopia control efficacy may vary.
5.2 Selecting a Treatment
To date, there have been no published clinical trials that have
tested specifically the appropriate point of intervention based
on either age or refractive status, to either prevent or delay the
onset or control the progression of myopia. Nevertheless, once
a myopic child has been identified, an appropriate treatment to
manage myopia progression must be selected based on
numerous patient specific factors. As described in Section 1,
there are important risk factors relating to myopia develop-
ment and progression. Children who possess multiple risk
factors may require more strategic management and frequent
review compared with those with little or no associated risk
factors. Other patient and treatment factors will also influence
treatment selection as described below.
5.2.1 Baseline Refractive Error. Earlier onset of myopia
often results in higher degrees of myopic refractive er-
ror.15,166,167 Although the progression rates across children
with different ages of onset may be similar, longer duration of
myopia progression results in a greater magnitude of myopia.15
Thus, a child’s age and baseline refractive error must be
considered together in the selection of treatment. Due to the
inherent risks of any treatment (contact lens, pharmaceuticals),
treatment is not generally advisable until the myopia is visually
significant; the IMI – Defining and Classifying Myopia Report
defines myopia as equal or more than 0.50 D.
Baseline refractive error will determine the availability of
treatment. For example, different MFSCL designs have varying
power ranges. Myopic children with low astigmatism may be
prescribed spherical MFSCLs, although practitioners must
consider the impact of the residual astigmatic refractive error
on visual acuity as uncorrected refractive astigmatism over 0.75
DC can lead to visual compromise.168 In these cases, residual
astigmatism can also be corrected by spectacles worn in addition
to MFSCLs, provided compliance can be assured. Currently, there
are no studies investigating toric MFSCLs for myopia control.
Spherical OK lenses are typically fitted to myopes with mild
astigmatism.169 Spherical OK lenses are generally fitted to
children with <1.50 D of corneal toricity. Toric periphery or
other lens designs may be available to those with higher
corneal toricity (based on differences in corneal elevation
across the two major meridians) and have also shown efficacy
for myopia control.170 Myopes with higher baseline myopia
may elect for partial correction with OK.171 Studies have
suggested individuals of younger age172,173 and higher degrees
of baseline refractive error may benefit most from OK.174,175
5.2.2 Binocular Vision Status. Studies have reported
differences in myopia control effects related to accommodative
and vergence factors. Thus, a child’s binocular vision status may
influence the efficacy of treatment. Greater myopia control
effects with progressive addition (spectacle) lenses (PALs) were
reported in children with larger lags of accommodation and near
esophoria.100 Children with lower lags of accommodation
(<1.01 D) have been found to experience greater myopia
control effects with prismatic bifocals (þ1.50 D add and 3 prism
diopters base-in in the near segment of each lens) compared
with standard executive bifocal spectacle lenses (þ1.50 D
add).176 In addition, children with lower baseline accommoda-
tive amplitude have greater myopia control response to OK
wear than those with higher baseline accommodative ampli-
tude.177
5.2.3 Ethnicity. There are limited studies investigating the
influence of ethnicity on treatments. A recent meta-analysis
suggested greater myopia control with atropine treatment in
children of Asian compared with European ethnicity178;
however, further prospective studies with appropriate simple
sizes are needed. Cultural and regional preferences for
particular treatments may need to be taken into account by
the practitioner. In time, as mechanisms underlying myopia are
better understood, research may help determine whether
certain treatments work better in particular populations.
5.3.4 Safety, Compliance and Cost Considerations.
Clinicians must determine whether children can safely self-
administer and comply with the treatment. For any contact
lens treatment, children (and/or parents/guardians) must
demonstrate appropriate contact lens handling skills for safe
and successful lens wear and maintenance. Clinicians must
be aware of contraindications to atropine eye drop use so
that it can be safely administered.
The annual cost of professional management and lens
materials or drug costs should be discussed with parents prior
to initiating treatment.179 Until these services are covered by
medical or vision insurance, costs incurred will be an out-of-
pocket expense. Due to the length and number of visits
required to appropriately manage these patients and the cost of
specialty contact lens materials, these treatments can come at a
significant cost. Parents and eye care practitioners should work
together to determine which modality may be best suited for a
particular child, based on the above factors.
5.3 Add Powers in MFSCL
Previous studies investigating myopia control with MFSCLs
have used several different lens designs.66,180–188 There are two
main categories of MFSCL designs: concentric ring or bifocal
lens design and progressive power or peripheral add lens
design. Concentric ring lens designs incorporate alternating
distance correction and treatment (plus power) zones to
provide two focal planes or simultaneous distance correction
and retinal myopic defocus. Progressive power lens designs
have a gradual change in curvature to provide a central zone of
distance correction with a progressive change to include a
relative plus power in the periphery. The majority of
investigated MFSCLs for myopia control incorporate a relative
þ2.00 D treatment correction creating simultaneous images on
the retina. Termed the ‘‘add’’, this power has some influence
on both peripheral and central optics of the eye.81,108,189,190
Some commercially available MFSCLs that were originally
designed for presbyopia correction have been used for off-
label myopia control treatment owing to studies that have
shown that these MFSCLs induce relative peripheral myopic
defocus.189–192 In clinical practice, it is recommended that a
MFSCL incorporating the patient’s full distance refractive
error and relative þ2.00 to þ2.50 D treatment correction be
initially selected, regardless of the design. Although MFSCLs
that manipulate optical defocus across larger areas of the
visual field have been suggested to result in greater myopia
control,193 to date, there has been no systematic investigation
comparing the efficacy of myopia control associated with
different add powers; however, studies are underway.194
Further discussion of this can be found in Section 8b. As
currently available MFSCLs, particularly lenses with higher
add powers, can significantly reduce quality of vision,195,196 it
is essential that visual acuity and quality of vision are
monitored. In cases where the patient experiences significant
reduction in visual acuity and/or subjective quality of vision
with the selected MFSCL, an over-refraction should be
conducted and incorporated into the lens power.197 Alterna-
tively, the add power may be reduced until acceptable vision
is achieved, or a different lens design may be trialed. The
impact of the add power on binocular vision function should
also be evaluated.
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5.4 Clinical Spectacle Myopia Control
Evidence on the efficacy of spectacle lenses with various
optical designs for myopia control are not as homogeneous as
that observed with contact lens options.193 The discrepancy
between the strong myopia control effects of plus defocus
observed in animal models versus the weaker and less
consistent effects in human myopia with spectacles could be
partially explained by noncompliance, limited amounts of
defocus, reduced wearing time due to visual distortion, and
restricted peripheral vision. As a result, myopia control
spectacles are generally reserved as a second-line treatment
for those who are either not suitable, not yet ready, or are
lacking motivation for myopia control contact lenses.
Undercorrection of myopia is still practiced in some
countries,179 although it has been shown to either have no
effect on progression or possibly even increases the rate of
myopia progression.198,199 Interestingly, a paper on delaying
correction of low myopia (<1 D) in 12-year-old Chinese
children found that those who were uncorrected showed 0.25
D less progression over 2 years than those who were fully
corrected.200 This relationship held even when controlling for
numerous genetic, refractive, and environmental factors,
indicating the large influence of optical correction. Caution
should be exercised in incorporating these results in clinical
care as they are modest, and priority should be to correct
ametropia and maximize acuity. It is likely the poor uncorrec-
tion results are related not only to wearing time compliance,
but amount of peripheral defocus and the effect on the
binocular vision system.201
Myopia control studies evaluating bifocal or PAL spectacle
lenses have used either aþ1.50202 orþ2.00 Add.76,77,105,203,204
In clinical practice, it may be more practical to prescribe the
near addition required to manage any evident accommodation
or vergence disorder205 to ensure visual comfort. Although
there is indication from one study that bifocal spectacle lenses
show better efficacy than PAL spectacles,76 the practitioner
should consider any esthetic issue with bifocal lenses, or
compliance and frame fitting issues with PALs in the
prescribing choice. The fitting seg line of bifocals should be
higher than that for presbyopic correction to ensure the add is
easily accessed and that enough myopic defocus is imposed on
the retina.52 Additionally, the frame should be regularly
adjusted to ensure that is appropriated fitted on the nasal
bridge, which is especially important in Asian children who
have lower nose bridges that results in frame slippage. Regular
adjustments to spectacle frames are recommended, as down-
ward slippage of PALs may reduce myopia control effects of the
near addition.43 Selecting PAL lens designs with shorter
corridors will similarly ensure the child is looking through
the near addition as much as possible.
Novel spectacle lens designs have been developed for
myopia control based on a peripheral defocus design and have
been found to be moderately successful in younger Asian
children with a family history of myopia.206 Other designs are
currently under development including multiple lenslet
designs.207
6. GUIDELINES FOR ADVICE AND CLINICAL CARE
6.1 Refractive Correction and Wearing Time
Children should be encouraged to wear their myopic
correction full time, as undercorrection of myopia has been
shown in some studies to increase myopia progression.198
The younger myopic child has a higher risk of progres-
sion,15,61 and consideration should also be given to correcting
any amblyogenic or strabismic risk factors such as significant
astigmatism, anisometropia, and binocular vision anomalies,
or the risk of developmental problems due to insufficient
functional vision.205 Although removing full distance myopic
refractive error correction during near work will reduce
accommodative demand and accommodative response during
near viewing, there have been no studies comparing myopia
progression in children wearing distance correction and
removal of distance correction during near work on myopia
progression.
OK wear should be encouraged every night for a minimum
of 8 hours per night to maximize correction for best unaided
vision during waking hours. Treatment effect of MFSCL is likely
to be positively correlated with wearing time; a study of novel
Defocus Incorporated Soft Contact (DISC) lenses reported an
inverse relationship between myopia progression and lens
wearing time. For the DISC lens design, a minimum of 5 hours
per day of lens wear was recommended to slow myopia
progression, with increasing efficacy up to 8 hours a day of
wear.182 For visual consistency, including ongoing acceptance
of MFSCL, a child should be recommended to wear MFSCLs
during school hours and for school work at home, with a
backup spectacle option (Section 6.6).
6.2 Indoor and Near Work Activity
As mentioned in Section 1.1, parents should be informed
that greater near work (hard copy or digitial) may influence
the development and progression of myopia36,37,39 Close
reading distance (20 cm) and continuous reading (>45
minutes) have been associated with greater odds of
myopia.22 Outdoor activity is associated with reduced
incidence of myopia in children, including those who usually
perform large amounts of near work.21,152 This suggests that
children should not be prevented from participating in near
work activity, but rather that regular breaks, appropriate
reading distances, and near-to-distance fixation changes
while reading and spending time on screens are taken, with
sufficient time outdoors also encouraged.
6.3 Outdoor Activity and Lighting
There is growing evidence that outdoor activity is associated
with lower incidence of myopia.21 Spending time outdoors
without requiring physical activity or direct sunlight exposure
appears to have a protective effect against myopia onset but
not for myopic progression, although the mechanism under-
lying this effect is not well understood.21 An increase in time
spent outdoors may result in greater protection, and studies
involving school-aged children have suggested a minimum of 8
to 15 hours of outdoor activity per week is required to achieve
clinically meaningful protection from myopiagenic stimu-
li.152,161,208–210
The protective effect of outdoor time for the onset of
myopia in humans is supported by animal studies that have
reported reduced eye growth with exposure to bright light and
the opposite effect, axial elongation, and myopia, resulting
from reduced light levels.211,212 High ambient lighting has been
shown to have protective effects against the development of
form deprivation myopia in Rhesus monkeys.213
Although good lighting should always be recommended for
any visual task, current advice to patients who are at risk of
developing myopia should be aimed at maximizing both indoor
and natural lighting and increasing outdoor time.26,27
6.4 Nutritional Advice
There is currently no conclusive evidence supporting any
definite link between myopia and nutrition or malnutri-
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tion.214,215 Some studies have linked myopic progression to
low-fat and low-carbohydrate intake,216 whereas diets high in
saturated fat and high cholesterol levels have also been linked
to increased axial length.217
A placebo-controlled clinical trial showed that the caffeine
metabolite 7-methylxanthine (7-MX) has the potential to
reduce eye growth in children.218 This medication is approved
as a treatment for myopia progression, but only in Denmark,
where these studies were undertaken. Although caffeine-like
stimulants may be part of nutritional advice for myopes in the
future, there is no current evidence to support nutritional
treatments for myopia control.219 Further detail on 7-MX can
be found in Section 7.2.
6.5 Advice to Patients on Minimizing Risk With
Contact Lenses or Atropine
Proper use of the prescribed treatment should be reviewed at
each visit, and patients should be educated on ways to
minimize risks of complications.
Contact Lens Wear:
 Always wash your hands before applying or removing
contact lenses.220,221
 Never swim or shower with contact lenses or expose the
contact lenses or lens storage case to water.222,223
 Don’t wear your contact lenses if you have a cold or are
unwell.224,225
 Daily disposable lenses are strongly encouraged. If you
wear reusable contact lenses, use new lens cleaning
solution each day226,227 and use a nonpreserved care
cleaning regimen such as hydrogen peroxide, if possible.
Replace your lens case at least every 3 to 6 months.225,228
Rinse the case with contact lens cleaning solution, rub,
tissue wipe, and air dry casing facing down.227
 Unless directed by your doctor (for OK), don’t sleep or
nap in your lenses.79,229
Atropine Use:
 Where available, unit dose atropine preparations are
preferable. In a multiuse bottle, to avoid contamination,
never touch the tip of the bottle to the eye or any other
surface and do not use the bottle past the expiration
date.230
6.6 Backup Corrections for Contact Lens Wear
For patients wearing daytime MFSCLs, it is recommended that
they use their contact lenses full time. As mentioned in Section
6.1, increasing lens wear time may provide greater myopia
control efficacy.182 Bifocal, PAL, or single-vision spectacles may
be prescribed for when children are not wearing contact
lenses. This prescribing decision may depend on the individ-
ual’s intended wearing time, refraction, and binocular vision
status in single-vision distance correction.
6.7 Review Schedule and Clinical Considerations
The follow-up schedules for patients receiving myopia control
treatments are determined by multiple factors such as the risks
of complications related to each option, the efficacy of
treatment in myopia control, and the patients’ compliance to
the treatments. Generally, patients undergoing any myopia
control treatment should be assessed at least every 6 months to
monitor safety and efficacy of treatment.
As discussed in Section 4.1, although cycloplegic autore-
fraction is typically measured in research studies, it can be used
in clinical practice on indication, at the practitioner’s
discretion, and where consistent with evidence-based best
practice. Consistent refraction techniques should be used to
ensure comparable clinical data. Similarly, axial length mea-
surement is an expected outcome measure of myopia control
research studies but is not used in widespread clinical practice.
Axial length measurement is a somewhat problematic diagnos-
tic factor in clinical myopia management but a useful
diagnostic factor in risk of myopia pathology. If available, axial
length measurements should be taken at least every 6 months.
The minimum recommended review schedule by treatment
type is shown in Figure 1, and clinical tests for myopia
management with low dose atropine eye drops, OK, MFSCLs,
and PAL/bifocal spectacles are detailed in Figure 2. Additional
aftercare visits are likely to be required for patients undergoing
OK or MFSCL treatment to optimize lens fit and to manage any
issues relating to quality of vision.
6.7.1 Atropine Eye Drops. A major clinical consideration
is the availability of atropine eye drops; currently, low dose
atropine eye drops are not commercially available and need to
be compounded by pharmacists who have appropriate sterile
laboratories. Facilities in laboratories will also dictate whether
clinicians have access to preserved and unpreserved formula-
tions of atropine.
Patients undergoing atropine therapy will require distance
refractive error correction. It is recommended that patients are
prescribed their full distance refractive correction; however,
single vision correction may not be suitable due to the
cycloplegic side effects of atropine. Patients may require near
addition correction to alleviate near visual symptoms (such as
PAL or bifocal spectacle lenses) and photochromic lenses or
additional sunglasses to relieve glare issues. The Atropine for
the Treatment of Myopia 2 (ATOM2) atropine study provided
photochromic lenses to all participants and offered PALs to
subjects who complained of near vision issues. They found that
only 7% of children on 0.01% atropine requested glasses.231
Although accommodative amplitude was only reduced by 2 to
3 D, further detail of the effect of low dose atropine on
accommodative lag, facility, and binocular vision function has
not yet been researched. Due to the potential impact of
atropine on accommodation, this should be assessed, and
appropriate management should be prescribed if there is
evidence of any accommodation and binocular vision dysfunc-
tion. Furthermore, studies establishing that low dose (0.01%)
FIGURE 1. Review schedule for myopia management based on
treatment type.
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atropine slows axial elongation to a clinically relevant level are
needed.75
6.7.2 OK. Numerous OK lens designs are available to
clinicians depending on their country of practice. To date,
there has been no systematic investigation comparing the
efficacy of myopia control induced by different OK lens
designs. If the full refractive error is not treated by OK
correction, single vision spectacle lenses for residual refractive
error correction will be required—this has shown efficacy for
myopia >6 D, where only 4 D was corrected with OK.171 Soft
contact lens wear for residual correction could be considered
in special cases where spectacle wear is not possible, or
compliance will not be achieved. In these cases, ocular health
should be monitored closely considering the resultant near-
constant contact lens wear. The suitability assessment and
fitting process for childhood myopia control OK is generally no
different than fitting for myopia correction, although in time
the lens designs used may differ—discussion of current and
future research on modifying OK lens designs for improved
myopia control efficacy can be found in Section 7.1.
6.7.3 MFSCL. There are various MFSCL designs used for
myopia control, and different designs will be available to
clinicians depending on their country of practice. Detail on add
power selection is provided in Section 5c. Currently one study
is underway evaluating distance center designs MFSCLs with a
representative low (þ1.50 D) and high add (þ2.50 D) on
myopia and axial length progressions in children with results
expected in the next year.194 Similar to OK, there are no
studies to date that have directly compared the efficacy of
myopia control induced by different MFSCL designs.232
Discussion of current and future research on modifying MFSCL
lens designs for improved myopia control efficacy can be found
in Section 7.1.
6.8 Treatment Duration
Regular review of patients undergoing myopia treatment
should be undertaken to consider whether myopia treatment
should be continued, modified, augmented with additional
treatment options, or halted altogether. Parents need to
appreciate when and why these different options may be
indicated, and when embarking on treatment, they should be
counseled as to the expected ‘‘life span’’ of different
treatments and the relative importance of a child’s age in
relation to the success or efficacy of treatments aimed at
slowing myopic progression.
Although influenced by many factors, myopia generally
progresses most rapidly during preteenage years (7–12 years),
subsequently slowing through adolescence and adult-
hood.9,61,233–235 Treatments are likely to be most effective at
younger ages when rapid progression is underway, and the
efficacy of some treatments may wane after the first 6 months
to 2 years of treatment.62,72,172,184,236 Further research is
required to fully support clinicians in determining when to
cease an individual’s treatment and the relative importance of
factors such as age, ethnicity, rate of progression, and level of
myopia when making this decision.
Long-term use of atropine may not be appropriate, as long-
term side effects have not been evaluated—the World Health
Organization currently recommends limiting treatment to 2
years.127 Most studies evaluating the effect of atropine have
been limited to 2-year periods (or less) of daily use,237 and it
may be beneficial to tail off dosage or dose frequency at the
end of treatment to minimize rebound effects (see Section
6.10).
MFSCLs and OK act as a spectacle-free form of vision
correction, and long-term use of MFSCLs and OK is not
contraindicated if ocular health is maintained.180,238
PALs can also be used for vision correction, but the long-
term, clinically meaningful myopia control treatment effect of
such lenses is small compared with contact lens corrections,
except in specific populations (see Section 5.4 and the IMI –
Interventions for Myopia Onset and Progression Re-
port).105,176,239 Bifocal spectacle lenses may show better
longevity of treatment.76
6.9 When to Change Treatment
Treatment may be stopped, switched to another form of
therapy, or augmented by combining with another treatment
modality when myopia progression is not sufficiently con-
trolled, in comparison to expected progression in single-vision
correction and when the average efficacy of the specific
treatment has been considered.
Judgement regarding what constitutes effective reduction
in progression in an individual patient is likely to depend on
ethnicity, age, level of myopia, and other factors. Data on the
child’s previous rate of progression is valuable, but not
always available, and growth curves for myopic children
wearing single vision spectacles or contact lenses may be
used as a reference.61,233,240 Where treatment is failing to
sufficiently control myopia progression, adjunct or combined
therapies may be warranted such as MFSCLs or OK combined
with low dose atropine to increase treatment effects,
although there is currently limited evidence of the beneficial
effect of combination treatment.241,242 Until further studies
are undertaken, practitioners should be cautious not to
overpromise the value of this combination therapy.
Compliance and safety issues may also require a change in
treatment modality or a halting of treatment. Poor tolerance
of visual side effects and/or treatment protocols may also
prompt cessation or change of treatment. Success rates in
persisting with treatment are likely to be related to motivation
and quality of pretreatment instruction and management of
expectation.
FIGURE 2. Clinical tests for myopia management.
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6.10 Long-Term Efficacy and Rebound Effects
Concern has been raised about long-term efficacy and potential
rebound effects for both optical and pharmaceutical interven-
tions. In the ATOM atropine studies, after cessation of
treatment, a rebound growth followed in the highest dosages,
and this rebound growth was limited in the other groups.231 In
European children, the effect of high dose atropine was
comparable to results from the ATOM study72 in the first year
of use.243 Parents and patients should be made aware that
myopia progression may accelerate after stopping atropine
treatment, but that despite this rebound effect the level of
myopia post-treatment will be, on average, less than it would
have been without treatment.74,231 Recommencement of
atropine treatment if post-treatment progression rates prove
unacceptable may be appropriate. In the ATOM study, Chia et
al.231 demonstrated that reintroduction of low dose atropine
(0.01%) after 1 year without treatment is effective in curbing
myopia progression and axial elongation in Chinese children.
Currently, no comparable studies on long-term use are
available, and it is yet to be investigated whether a decrease
in dosage, after starting with high dose atropine, has both the
beneficial effect of the high reduction in the first year and
stabilization afterward.
Evidence of rebound effects in optical devices has been
equivocal. A study of children wearing PALs for 1 year who
were then switched to single vision glasses for 1 year showed
no rebound compared with those wearing single vision
alone.52 Cheng et al.184 suggested no rebound effect with a
MFSCL for myopia control that was worn for 1 to 2 years
compared with the control group after a subsequent 1.5 years
of SV SCL wear, although the myopia control effect was limited
to the first 6 months of treatment. On the other hand,
discontinuation of OK lens wear before age 14 has been shown
to lead to a more rapid increase in axial length over a 7-month
period, faster than concurrent single vision spectacle wearing
controls; however, this slows again with resumed lens wear
after another 6 months.244 This likely indicates that OK wear
should not be discontinued before age 14.
Although the efficacy over more than 5 years of myopia
control treatment, plateau, and rebound effects has not been
established, current evidence still suggests that initiating some
form of myopia control treatment is better than single vision
correction.
6.11 When to End Treatment
Goss and Winkler reported that the mean age of myopia
stabilization is around 14 to 16 years of age.245 A later study in
an ethnically diverse population confirmed this finding, with a
mean (6SD) age of stabilization of 15.6 6 4.) years.246
Although these figures support a commonly held belief that
myopia usually progresses until the mid-teens, the large SD of
the latter study suggests that a sizeable proportion of the
community will continue to progress into their 20s (the Comet
study showed that 95% of myopes stabilized by 24 years of
age).246 Indeed, mean (6SD) myopia progression over an
average of 8 years in a Scandinavian case series cohort with age
of 20 to 24 was 0.45 6 0.71 D. In 45% of cases, progression
was ‡0.5 D. Although the average annual change is small, these
data support the notion of continued potential for progression
into adulthood. However, there is a scarcity of longitudinal data
showing the normal course of myopia progression after the age
of 18, in both Western and Eastern populations (see Section
6.12 on late-onset myopia).
Thus, at this time, the impact of myopia control treatments
on age of cessation of myopia progression is unknown. This
question has multiple ramifications. For example, would a
child likely to progress without treatment until the age of 15
cease progression, albeit at a slower rate, at say age 12? If a
clinician decided, from successive refractive error measure-
ments, that the child had ceased progression at age 12, and
therefore stopped treatment and returned the child to simple
corrective myopia lenses, would we expect the refraction to
remain stable? Ideally, cessation of treatment would also
encompass a subsequent period of observation to evaluate
the risk of further progression, with a view to reinstituting
treatment if necessary.
Close monitoring by the clinician is important on treatment
cessation, so that any apparent acceleration in progression can
be quickly addressed by reinstituting treatment. Furthermore,
there are legal and ethical issues related to treatment
intervention that might need to be considered. For more detail
see the IMI – Industry Guidelines and Ethical Considerations
for Myopia Control Report.
6.12 Late-Onset Myopia
As noted above, there are scarce population-based longitudinal
data characterizing progression of myopia after the school
years. In one large study from the United Kingdom, it was
observed that 49% of 44 year olds were myopic, with a
surprising 81% being late onset (16 years or older).247 There is
also considerable evidence of myopia onset and progression
among specific occupational groups during demanding univer-
sity education courses. Medicine, law, and engineering are a
few examples.248–250
The rationale for attempting progression control in late-
onset myopia is somewhat different than younger ages, where
the key risk is to avoid high myopia, with its attendant sight-
threatening risks. It is unlikely that late-onset myopes will
progress to high myopia; however, any increase in myopia is
associated with increasing risk of disease, and this should be
borne in mind.30 The same treatments and protocols as applied
to children and described above will generally be applicable to
later-onset myopes.
Of concern, and having received little attention in the
literature to date, is the moderate myope who undertakes an
intense course of study and is at risk of progressing to high
myopia. Anecdotally, it would seem that the numbers of
individuals at risk of developing pathologic myopia is
relatively low, but application of myopia control treatments
for this group is potentially of equal importance to young age
groups. Appropriate management requires judicious atten-
tion and follow-up by clinicians. It is evident that more
research is needed to better quantify adult myopia progres-
sion.
6.13 High Myopia: Special Considerations
High myopia (>5.00–6.00 D) poses a greater risk of ocular
complications that may lead to visual impairment or even
blindness. Higher incidences of cataracts,251,252 glauco-
ma,253,254 and retinal abnormalities including chorioretinal
atrophy and posterior staphyloma255,256 have been reported.
Although these pathologies are typically observed in
adulthood, children too can be affected by retinal patholo-
gies.257,258 A retrospective chart review of children aged 10
years or younger with high myopia found peripheral retinal
changes in 33% of eyes including lattice degeneration (20%),
white without pressure (11%), retinal holes with subretinal
fluid (4%), and vitreoretinal tuft (2%).259 In young teenage
myopes with mean spherical equivalent refraction of 8.41 6
1.60 D, the most frequent retinal lesions were optic nerve
crescents (52.5%), white without pressure (51.7%), lattice
degeneration (5.8%) microcystoid degeneration (5%), and
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pigmentary degeneration (4.2%). Axial length longer than 26
mm was a significant risk factor for peripheral lesions, optic
nerve crescents, and white without pressure.260
Patients should be advised that myopia, especially high
myopia or when axial length is longer than 26 mm, may have a
higher risk of developing a retinal detachment.260 Patients with
such characteristics should be provided with the warning signs
and symptoms of retinal detachment and reviewed with annual
fundus examination through dilated pupils, as described in
Section 4.1. Further detail on the pathologic complications of
myopia can be found in the IMI – Defining and Classifying
Myopia Report.
7. FUTURE RESEARCH DIRECTIONS ON INTERVENTION
AND TREATMENT
7.1 OK and MFSCL Optimization
Studies have suggested the potential benefits of increasing the
degree and extent of peripheral myopic defocus to improved
efficacy of myopia control.261 An association between greater
myopic defocus on the superior retina, in children wearing
PALs, and slower myopia progression has been reported.262
Larger reductions in myopia progression in children fitted with
MFSCLs compared with PALs may be attributable to greater
peripheral defocus changes induced by MFSCLs.193 This has
motivated the use of customised OK and MFSCLs for myopia
control in clinical practice.
A previous study attempted to increase the amount of
midperipheral corneal steepening induced by OK to induce
greater myopic defocus onto the peripheral retina. Reduc-
tion of the optic zone diameter of OK lenses from 6 to 5 mm
to increase the retinal exposure to myopia defocus was
investigated. However, these OK lens parameter changes did
not cause significant changes to corneal topography.263
More recently, a retrospective study found that participants
fit with a four-curve OK lens design demonstrated a
significantly larger central distance zone of treatment
compared with a five-curve lens design, but there was no
difference in the power or width of the midperipheral
steepened zone, and the effect on relative peripheral
refraction was not measured.264 This is an area for further
research.
There are several software tools available to customize OK
lens designs, which are provided in the Supplementary
Material. Practitioner training is recommended to understand
the limits of each program. Compatibility with topographic
equipment, the ease of use, and the possibility to work with a
local laboratory may influence which of the following must be
selected in practice. However, more research is needed to
understand if and how we can modify OK lens designs to
improve efficacy of myopia control.
Similar to OK lenses, investigations to increase the
degree and extent of peripheral myopic defocus induced
by soft contact lens designs in an attempt to improve
myopia control efficacy are currently underway. Using
commercially available distance-centered designs, it has
been shown that only higher adds of þ3.00 and þ4.00 can
significantly modify the peripheral refractive pattern to
relative myopia compared with the central refraction,192 but
unfortunately, the visual outcomes in these currently
available higher add MFSCLs have been shown to be poorly
tolerated in children.196 The Bifocal Lenses in Nearsighted
Kids (BLINK) study is the first clinical trial to evaluate
distance center design MFSCLs with a representative low
(þ1.50 D) and high add (þ2.50 D) on myopia and axial
length progression in children with results expected in the
next year.194
7.2 7-MX, Scleral Reinforcement, Circadian
Rhythms, and Other Future Treatments
As mentioned in Section 6.4, 7-MX has been shown to slow
myopia in children and to suppress axial elongation in form
deprivation myopia in the rabbit and the guinea pig265–267
and lens-induced myopia in Rhesus monkeys.268 An adeno-
sine-antagonist, 7-MX is a metabolite of caffeine and
theobromine, was theorized by the authors to control axial
elongation by thickening and strengthening collagen fibrils
in the sclera, and is approved for treatment of progressive
myopia in Denmark. Intriguingly, others have speculated that
if a metabolite of caffeine in the form of oral 7-MX has shown
myopia control efficacy, perhaps caffeine in the form of an
eye drop might have a beneficial effect on myopia
progression. Results on topical treatment to date are limited
to a paper from the 2017 International Myopia Conference
showing both a thickening of the choroid and a reduction in
myopia progression in the Rhesus monkey.269
If ocular pathologies such as retinal detachment and myopic
maculopathy, associated with myopia progression, are due to
the thinning of the sclera and the stresses created by the
stretching of the eye, then there may be some role for
strengthening the sclera. Although there have been attempts to
strengthen the sclera via scleral reinforcement surgeries,270
cross-linking,271,272 and with injectables,273 none of these
methods have a long record of success in humans. Posterior
scleral buckling has been reported in a large case series to slow
axial elongation and to reduce vision loss, but it has yet to be
duplicated by other researchers.274,275
Future treaments may also be designed to interact with
circadian rhythms and night time light exposure. In the
chick model, it has been shown that not only does
disruption of circadian rhythms by light exposure at night
lead to abolition of diurnal variations in ocular structures
and promote myopic eye growth, but that the control of eye
growth is influenced differentially by the time of day during
which the eye is exposed to hyperopic and myopic
defocus.276 In humans, several recent studies have reported
an association between myopia and poor or disrupted
sleep,277–279 and significant differences in serum melatonin,
a key biomarker of circadian rhythm, has been found in
myopic compared with nonmyopic young adults.280 Further
research is required to fully appreciate the role of ocular and
systemic circadian rhythms in controlling eye growth and
how timing of antimyopia interventions may interact with
the circadian system. However, current knowledge supports
practitioners advising parents on the benefits of encourag-
ing natural circadian rhythms as part of a myopia interven-
tion strategy.
The coming years are likely to result in a number of studies
on various methods to control myopia, including novel
medications, novel spectacle, and contact and OK designs,
as well as combination treatments. The ideal contact lens for
myopia control will likely include modification to all
mechanisms postulated in myopia progression—relative
peripheral hyperopia, higher-order aberrations, accommoda-
tion, and binocular vision—and may additionally include low
dose atropine delivery, modification to indoor lighting,281 and
even biometric feedback on near working distance and time
spent outdoors.187 Nutritional and lifestyle interventions may
play a bigger role, as described above. Practitioners will have
to stay informed on future developments and incorporate
these treatments into their practice as the evidence is
revealed.
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8. CLINICAL REFERENCES, EDUCATION AND
COMMUNICATION
8.1 Key Papers, Websites, and Courses for
Practitioner Reference
Keeping up to date with the latest literature can be a challenge
for the clinician—key meta-analysis papers and systematic
reviews can help to summarize research results. Open access
articles are freely available for both the practitioner and the
research-interested parent to download. Links for these papers
are available in the Supplementary Material, along with detail
of online practitioner resources, forums, and relevant clinical
conferences for further information and support.
8.2 Recommendations for Communication Tools
A key challenge when communicating the impact of myopia is
explaining the long-term risks such as the higher risk of
pathologies associated with increasing levels of myopia, as well
the short-term choices, such as altering the visual environment
to increasing outdoor time for premyopes or fitting a child with
myopia-controlling contact lenses. This is particularly complex
when the short-term choices may include additional risk, such
as those associated with pediatric contact lens wear. Practi-
tioners also report difficulty in communicating a research-
based message that may conflict with the more conservative
messages from other health professionals such as pediatricians,
general practitioners, and eye care providers. Development of
communication tools for practitioners that strongly communi-
cate the benefits of myopia management, balanced with the
risks and the currently unanswered research questions, will
assist in providing evidence-based information to the parent to
inform health choices for their myopic children.
8.3 Continuing Education and Accreditation of
Practitioners
Research in myopia and myopia control is a continually
evolving field. To be able to provide current evidence-based
myopia management, clinicians need to be informed of the
most up-to-date research. It is therefore important that
clinicians stay current with their continuing education,
particularly in the area of myopia and myopia control. The
IMI – Industry Guidelines and Ethical Considerations in Myopia
Control Report describes ‘‘an urgent need to create standard-
ized educational materials on myopia risk and myopia control
treatments. Such educational materials should cover areas such
as epidemiology, the public health burden due to myopia,
contemporary research in myopia control, interventional
options and best clinical practices for myopia control.’’ The
IMI suite of reports and several other groups are expending
efforts to provide this information to clinicians.
The IMI – Industry Guidelines and Ethical Considerations in
Myopia Control Report discusses potential accreditation or
training of eye care practitioners in prescribing myopia control
treatments. Ensuring a comprehensive understanding of
myopia complications, treatment complications, expected
clinical results, and fitting assistance is worthwhile for both
industry and prescribers to ensure best outcomes for pediatric
patients.
In some countries, eye care providers may require
endorsement to prescribe drugs, including atropine eye drops.
Similarly, certification examinations may be required before
practitioners are allowed to order and fit OK or other contact
lenses. When providing myopia management services, it is
expected that eye care providers have the appropriate training
and necessary certification to care for children and fit contact
lenses and/or prescribe ocular medications. It is also important
to be able to manange or comanage potential adverse events.
Continuing professional development is not mandatory across
the global eye care profession, and consideration of best
practice educational principles is important to ensuring
evidence-based patient care.
Key papers for practitioner reference and various tools to
assist with clinical issues such as treatment selection and
clinician–patient communication have been detailed in the
Supplementary Material. Short courses in myopia management
are increasingly popular, and there may be a need for
university-affiliated postgraduate courses in myopia manage-
ment.
Acknowledgments
The authors thank Sarah Kochik (University of California Berkeley
School of Optometry) (Sections 3.4, 5.4, 6.6) and Lyle Gray
(Glasgow Caledonian University) (Section 6.12). The authors also
thank the members of the International Myopia Institute commit-
tees for review and suggestions on the manuscript.
Supported by the International Myopia Institute. The publication
costs of the International Myopia Institute reports were supported
by donations from the Brien Holden Vision Institute, Carl Zeiss
Vision, Coopervision, Essilor, Alcon, and Vision Impact Institute.
Disclosure: K.L. Gifford, Alcon (R), CooperVision (C, R), Essilor
(C), Menicon (C, R), Myopia Profile Pty Ltd. (I), Visioneering
Technologies (R); K. Richdale, Alcon Euclid (F), Novartis (C); P.
Kang, Bausch þ Lomb Australia (F), CooperVision Australia (F),
CooperVision USA (F), Paragon Vision Sciences USA (F); T.A. Aller,
Essilor (C, R), Johnson & Johnson (I), Nevakar (R), Pentavision (R),
Reopia (C), Specialeyes, LLC (F), Treehouse Eyes, LLC (F), Vision
CRC, P; Visioneering Technologies, Inc. (F, C, R), P; C.S. Lam,
Hoya Corporation (F), Johnson & Johnson (F), P; Y.M. Liu, Paragon
(F, C); L. Michaud, Allergan (R), Bausch & Lomb (R), Blanchard
Labs (F, R), CooperVision (F, R), Johnson & Johnson (F), Shire (R),
P; J. Mulder, None; J.B. Orr, None; K.A. Rose, None; K.J.
Saunders, None; D. Seidel, None; J.W.L. Tideman, None; P.
Sankaridurg, Brien Holden Vision Institute (E), P
References
1. Farbrother JE, Kirov G, Owen MJ, Guggenheim JA. Family
aggregation of high myopia: estimation of the sibling
recurrence risk ratio. Invest Ophthalmol Vis Sci. 2004;45:
2873–2878.
2. Mutti DO, Mitchell GL, Moeschberger ML, Jones LA, Zadnik
K. Parental myopia, near work, school achievement, and
children’s refractive error. Invest Ophthalmol Vis Sci. 2002;
43:3633–3640.
3. Gwiazda J, Thorn F, Bauer J, Held R. Emmetropization and
the Progression of Manifest Refraction in Children Fol-
lowed From Infancy to Puberty. Oxford, Royaume-Uni:
Pergamon Press; 1993.
4. Wildsoet CF. Active emmetropization: evidence for its
existence and ramifications for clinical practice. Ophthalmic
Physiol Opt. 1997;17:279–290.
5. Breslin KM, O’Donoghue L, Saunders KJ. A prospective study
of spherical refractive error and ocular components among
Northern Irish schoolchildren (the NICER study). Invest
Ophthalmol Vis Sci. 2013;54:4843–4850.
6. Morgan I, Rose K. How genetic is school myopia? Prog
Retinal Eye Res. 2005;24:1–38.
7. Mutti DO, Hayes JR, Mitchell GL, et al. Refractive error, axial
length, and relative peripheral refractive error before and
after the onset of myopia. Invest Ophthalmol Vis Sci. 2007;
48:2510–2519.
IMI – Clinical Management Guidelines IOVS j Special Issue j Vol. 60 j No. 3 j M196
Downloaded from iovs.arvojournals.org on 05/03/2019
8. Jones-Jordan LA, Sinnott LT, Manny RE, et al. Early childhood
refractive error and parental history of myopia as predictors
of myopia. Invest Ophthalmol Vis Sci. 2010;51:115–121.
9. McCullough SJ, O’Donoghue L, Saunders KJ. Six year
refractive change among white children and young adults:
evidence for significant increase in myopia among white UK
children. PLoS One. 2016;11:e0146332.
10. Zadnik K, Sinnott LT, Cotter SA, et al. Prediction of juvenile-
onset myopia. JAMA Ophthalmol. 2015;133:683–689.
11. McBrien NA, Millodot M. A biometric investigation of late
onset myopic eyes. Acta Ophthalmologica. 1987;65:461–
468.
12. Jiang BC. Parameters of accommodative and vergence
systems and the development of late-onset myopia. Invest
Ophthalmol Vis Sci. 1995;36:1737–1742.
13. Price H, Allen PM, Radhakrishnan H, et al. The Cambridge
Anti-myopia Study: variables associated with myopia pro-
gression. Optom Vis Sci. 2013;90:1274–1283.
14. Sankaridurg PR, Holden BA. Practical applications to modify
and control the development of ametropia. Eye. 2014;28:
134–141.
15. Chua SY, Sabanayagam C, Cheung YB, et al. Age of onset of
myopia predicts risk of high myopia in later childhood in
myopic Singapore children. Ophthalmic Physiol Opt. 2016;
36:388–394.
16. Jones-Jordan LA, Sinnott LT, Graham ND, et al. The
contributions of near work and outdoor activity to the
correlation between siblings in the Collaborative Longitudi-
nal Evaluation of Ethnicity and Refractive Error (CLEERE)
Study. Invest Ophthalmol Vis Sci. 2014;55:6333–6339.
17. Wu LJ, Wang YX, You QS, et al. Risk factors of myopic shift
among primary school children in Beijing, China: a
prospective study. Int J Med Sci. 2015;12:633–638.
18. Ip JM, Huynh SC, Robaei D, et al. Ethnic differences in
refraction and ocular biometry in a population-based sample
of 11-15-year-old Australian children. Eye. 2008;22:649–656.
19. Rudnicka AR, Owen CG, Nightingale CM, Cook DG, Whin-
cup PH. Ethnic differences in the prevalence of myopia and
ocular biometry in 10- and 11-year-old children: the Child
Heart and Health Study in England (CHASE). Invest
Ophthalmol Vis Sci. 2010;51:6270–6276.
20. Rose KA, Morgan IG, Ip J, et al. Outdoor activity reduces the
prevalence of myopia in children. Ophthalmology. 2008;
115:1279–1285.
21. Xiong S, Sankaridurg P, Naduvilath T, et al. Time spent in
outdoor activities in relation to myopia prevention and
control: a meta-analysis and systematic review. Acta Oph-
thalmol. 2017;95:551–566.
22. Li SM, Li SY, Kang MT, et al. Near work related parameters
and myopia in Chinese children: the Anyang Childhood Eye
Study. PLoS One. 2015;10:e0134514.
23. Ip JM, Saw S-M, Rose KA, et al. Role of near work in myopia:
findings in a sample of Australian school children. Invest
Ophthalmol Vis Sci. 2008;49:2903–2910.
24. Aldossari H, Suheimat M, Atchison DA, Schmid KL. Effect of
accommodation on peripheral eye lengths of emmetropes
and myopes. Optom Vis Sci. 2017;94:361–369.
25. Woodman EC, Read SA, Collins MJ, et al. Axial elongation
following prolonged near work in myopes and emmetropes.
Br J Ophthalmol. 2011;95:652–656.
26. Hua WJ, Jin JX, Wu XY, et al. Elevated light levels in schools
have a protective effect on myopia. Ophthalmic Physiol Opt.
2015;35:252–262.
27. Read SA, Collins MJ, Vincent SJ. Light exposure and physical
activity in myopic and emmetropic children. Optom Vis Sci.
2014;91:330–341.
28. Torii H, Ohnuma K, Kurihara T, Tsubota K, Negishi K. Violet
light transmission is related to myopia progression in adult
high myopia. Sci Rep. 2017;7:14523.
29. Williams KM, Bentham GC, Young IS, et al. Association
between myopia, ultraviolet B radiation exposure, serum
vitamin D concentrations, and genetic polymorphisms in
vitamin D metabolic pathways in a multicountry European
study. JAMA Ophthalmol. 2017;135:47–53.
30. Flitcroft DI. The complex interactions of retinal, optical and
environmental factors in myopia aetiology. Prog Retin Eye
Res. 2012;31:622–660.
31. Dolgin E. The myopia boom. Nature. 2015;519:276–278.
32. Rose KA, French AN, Morgan IG. Environmental factors and
myopia: paradoxes and prospects for prevention. Asia Pac J
Ophthalmol (Phila). 2016;5:403–410.
33. Lam CSY, Goh WSH. The incidence of refractive errors
among schoolchildren in Hong Kong and its relationship
with the optical components. Clin Exp Optom. 1991;74:97–
103.
34. Rose KA, Morgan IG, Smith W, Burlutsky G, Mitchell P, Saw
SM. Myopia, lifestyle, and schooling in students of Chinese
ethnicity in Singapore and Sydney. Arch Ophthalmol. 2008;
126:527–530.
35. Lam CS-Y, Lam C-H, Cheng SC-K, Chan LY-L. Prevalence of
myopia among Hong Kong Chinese schoolchildren: changes
over two decades. Ophthalmic Physiol Opt. 2012;32:17–24.
36. Zylbermann R, Landau D, Berson D. The influence of study
habits on myopia in Jewish children. J Pediatr Ophthalmol
Strabismus. 1993;30:319–322.
37. Ben-Simon GJ, Peiss M, Anis E, Nakra T, Luski A, Spierer A.
Spectacle use and reduced unaided vision in third grade
students: a comparative study in different educational
settings. Clin Exp Optom. 2004;87:175–179.
38. Kinge B, Midelfart A, Jacobsen G, Rystad J. The influence of
near-work on development of myopia among university
students. A three-year longitudinal study among engineering
students in Norway. Acta Ophthalmol Scand. 2000;78:26–
29.
39. Morgan IG, Rose KA. Myopia and international educational
performance. Ophthalmic Physiol Opt. 2013;33:329–338.
40. Mountjoy E, Davies NM, Plotnikov D, et al. Education and
myopia: assessing the direction of causality by mendelian
randomisation. BMJ. 2018; 361:k2022.
41. Verhoeven VJM, Buitendijk GHS, Rivadeneira F, et al.
Education influences the role of genetics in myopia. Eur J
Epidemiol. 2013;28:973–980.
42. Gwiazda J, Bauer J, Thorn F, Held R. A dynamic relationship
between myopia and blur Driven accommodation in school-
aged children. Vision Res. 1995;35:1299–1304.
43. Nakatsuka C, Hasebe S, Nonaka F, Ohtsuki H. Accommoda-
tive lag under habitual seeing conditions: comparison
between myopic and emmetropic children. Jap J Ophthal-
mol. 2005;49:189–194.
44. Drobe B, de Saint-Andre´ R. The pre-myopic syndrome.
Ophthalmic Physiol Opt. 1995;15:375–378.
45. Allen PM, O’Leary DJ. Accommodation functions: co-
dependency and relationship to refractive error. Vision
Res. 2006;46:491–505.
46. Pandian A, Sankaridurg PR, Naduvilath T, et al. Accommo-
dative facility in eyes with and without myopia. Invest
Ophthalmol Vis Sci. 2006;47:4725–4731.
47. Gwiazda J, Grice K, Thorn F. Response AC/A ratios are
elevated in myopic children. Ophthalmic Physiol Opt. 1999;
19:173–179.
48. Gwiazda J, Thorn F, Held R. Accommodation, accommoda-
tive convergence, and response AC/A ratios before and at the
IMI – Clinical Management Guidelines IOVS j Special Issue j Vol. 60 j No. 3 j M197
Downloaded from iovs.arvojournals.org on 05/03/2019
onset of myopia in children. Optom Vis Sci. 2005;82:273–
278.
49. Mutti DO, Jones LA, Moeschberger ML, Zadnik K. AC/A ratio,
age, and refractive error in children. Invest Ophthalmol Vis
Sci. 2000;41:2469–2478.
50. Gwiazda J, Hyman L, Hussein M, et al. A randomized clinical
trial of progressive addition lenses versus single vision lenses
on the progression of myopia in children. Invest Ophthal-
mol Vis Sci. 2003;44:1492–1500.
51. Rosenfield M, Desai R, Portello JK. Do progressing myopes
show reduced accommodative responses? Optom Vis Sci.
2002;79:268–273.
52. Berntsen DA, Sinnott LT, Mutti DO, Zadnik K. A randomized
trial using progressive addition lenses to evaluate theories of
myopia progression in children with a high lag of
accommodation. Invest Ophthalmol Vis Sci. 2012;53:640–
649.
53. Berntsen DA, Sinnott LT, Mutti DO, Zadnik K. Accommoda-
tive lag and juvenile-onset myopia progression in children
wearing refractive correction. Vision Res. 2011;51:1039–
1046.
54. Jones LA, Sinnott LT, Mutti DO, Mitchell GL, Moeschberger
ML, Zadnik K. Parental history of myopia, sports and outdoor
activities, and future myopia. Invest Ophthalmol Vis Sci.
2007;48:3524–3532.
55. Ramamurthy D, Lin Chua SY, Saw SM. A review of
environmental risk factors for myopia during early life,
childhood and adolescence. Clin Exp Optom. 2015;98:497–
506.
56. Gwiazda J, Thorn F, Held R. Accommodation, accommoda-
tive convergence, and response AC/A ratios before and at the
onset of myopia in children. Optom Vis Sci. 2005;82:273–
278.
57. Tideman JW, Snabel MC, Tedja MS, et al. Association of axial
length with risk of uncorrectable visual impairment for
Europeans with myopia. JAMA Ophthalmol. 2016;134:1355–
1363.
58. Dave T, Ruston D. Current trends in modern orthokeratol-
ogy. Ophthalmic Physiol Opt. 1998;18:224–233.
59. Smith EL III, Hung LF, Arumugam B. Visual regulation of
refractive development: insights from animal studies. Eye.
2014;28:180–188.
60. Stone RA, Pardue MT, Iuvone PM, Khurana TS. Pharmacology
of myopia and potential role for intrinsic retinal circadian
rhythms. Exp Eye Res. 2013;114:35–47.
61. Donovan L, Sankaridurg P, Ho A, Naduvilath T, Smith EL III,
Holden BA. Myopia progression rates in urban children
wearing single-vision spectacles. Optom Vis Sci. 2012;89:27–
32.
62. Hiraoka T, Kakita T, Okamoto F, Takahashi H, Oshika T. Long-
term effect of overnight orthokeratology on axial length
elongation in childhood myopia: a 5-year follow-up study.
Invest Ophthalmol Vis Sci. 2012;53:3913–3919.
63. Santodomingo-Rubido J, Villa-Collar C, Gilmartin B, Gutier-
rez-Ortega R. Myopia control with orthokeratology contact
lenses in Spain: refractive and biometric changes. Invest
Ophthalmol Vis Sci. 2012;53:5060–5065.
64. Cho P, Cheung SW. Retardation of Myopia in Orthokeratol-
ogy (ROMIO) Study: a 2-year randomized clinical trial. Invest
Ophthalmol Vis Sci. 2012;53:7077–7085.
65. Walline JJ, Jones LA, Sinnott LT. Corneal reshaping and
myopia progression. Br J Ophthalmol. 2009;93:1181–1185.
66. Anstice NS, Phillips JR. Effect of dual-focus soft contact lens
wear on axial myopia progression in children. Ophthalmol-
ogy. 2011;118:1152–1161.
67. Lam CS, Tang WC, Tse DY, Tang YY, To CH. Defocus
Incorporated Soft Contact (DISC) lens slows myopia
progression in Hong Kong Chinese schoolchildren: a 2-year
randomised clinical trial. Br J Ophthalmol. 2014;98:40–45.
68. Sankaridurg P, Holden B, Smith E III, et al. Decrease in rate of
myopia progression with a contact lens designed to reduce
relative peripheral hyperopia: one-year results. Invest
Ophthalmol Vis Sci. 2011;52:9362–9367.
69. Aller TA, Liu M, Wildsoet CF. Myopia control with bifocal
contact lenses: a randomized clinical trial. Optom Vis Sci.
2016;93:344–352.
70. Cooper J, O’Connor B, Watanabe R, et al. Case series analysis
of myopic progression control with a unique extended
depth of focus multifocal contact lens. Eye Contact Lens.
2018;44:e16–e24.
71. Rah MJ, Walline JJ, Jones-Jordan LA, et al. Vision specific
quality of life of pediatric contact lens wearers. Optom Vis
Sci. 2010;87:560–566.
72. Chua WH, Balakrishnan V, Chan YH, et al. Atropine for the
treatment of childhood myopia. Ophthalmology. 2006;113:
2285–2291.
73. Chia A, Chua WH, Cheung YB, et al. Atropine for the
treatment of childhood myopia: safety and efficacy of 0.5%,
0.1%, and 0.01% doses (Atropine for the Treatment of
Myopia 2). Ophthalmology. 2012;119:347–354.
74. Tong L, Huang XL, Koh AL, Zhang X, Tan DT, Chua WH.
Atropine for the treatment of childhood myopia: effect on
myopia progression after cessation of atropine. Ophthal-
mology. 2009;116:572–579.
75. Bullimore MA, Berntsen DA. Low Dose atropine for myopia
control: considering all the data. JAMA Ophthalmol. 2018;
136:303.
76. Cheng D, Schmid KL, Woo GC, Drobe B. Randomized trial of
effect of bifocal and prismatic bifocal spectacles on myopic
progression: two-year results. Arch Ophthalmol. 2010;128:
12–19.
77. Gwiazda J, Hyman L, Hussein M, et al. A randomized clinical
trial of progressive addition lenses versus single vision lenses
on the progression of myopia in children. Invest Ophthal-
mol Vis Sci. 2003;44:1492–1500.
78. Bullimore MA, Sinnott LT, Jones-Jordan LA. The risk of
microbial keratitis with overnight corneal reshaping lenses.
Optom Vis Sci. 2013;90:937–944.
79. Chalmers RL, Wagner H, Mitchell GL, et al. Age and other
risk factors for corneal infiltrative and inflammatory events
in young soft contact lens wearers from the Contact Lens
Assessment in Youth (CLAY) study. Invest Ophthalmol Vis
Sci. 2011;52:6690–6696.
80. Bullimore MA. The safety of soft contact lenses in children.
Optom Vis Sci. 2017;94:638–646.
81. Gong CR, Troilo D, Richdale K. Accommodation and phoria
in children wearing multifocal contact lenses. Optom Vision
Sci. 2017;94:353–360.
82. Gifford K, Gifford P, Hendicott PL, Schmid KL. Near
binocular visual function in young adult orthokeratology
versus soft contact lens wearers. Cont Lens Anterior Eye.
2017;40:184–189.
83. Akorn, Inc. Atropine Sulfate Ophthalmic Solution, USP 1%
(Package Insert). Available at: http://www.akorn.com/docu
ments/catalog/package_inserts/17478-215-02.pdf. Accessed
August 10, 2018.
84. Loughman J, Flitcroft DI. The acceptability and visual impact
of 0.01% atropine in a Caucasian population. Br J
Ophthalmol. 2016;100:1525–1529.
85. Huang J, Wen D, Wang Q, et al. Efficacy comparison of 16
interventions for myopia control in children: a network
meta-analysis. Ophthalmology. 2016;123:697–708.
86. U.S. Food & Drug Administration. Understanding Unap-
proved Use of Approved Drugs ‘‘Off Label’’. Available at:
IMI – Clinical Management Guidelines IOVS j Special Issue j Vol. 60 j No. 3 j M198
Downloaded from iovs.arvojournals.org on 05/03/2019
https://www.fda.gov/forpatients/other/offlabel/default.htm.
Accessed August 10, 2018.
87. The College of Optomertrists. Optometrists’ Formulary.
Available at: https://www.college-optometrists.org/guidance/
optometrists-formulary.html. Accessed September 24, 2018.
88. European Commission. Off-Label Use of Medicinal Products.
Available at: https://ec.europa.eu/health/sites/health/files/
files/committee/stamp/stamp6_off_label_use_background.
pdf. Accessed August 10, 2018.
89. Australian Prescriber. Off-Label Prescribing. Available at:
https://www.nps.org.au/australian-prescriber/articles/off-
label-prescribing-6. Accessed August 10, 2018.
90. The Best Practice Advocacy Centre New Zealand. Upfront:
Unapproved Medicines and Unapproved Uses of Medicines:
Keeping Prescribers and Patients Safe. Available at: https://
bpac.org.nz/bpj/2013/march/unapproved-medicines.aspx.
Accessed August 10, 2018.
91. Health Canada. Medical Devices Active Licence Listing
(MDALL). Active License Search: MiSight. Available at:
https://health-products.canada.ca/mdall-limh/. Accessed
September 24, 2018.
92. Lam C. Diagnostic drugs. In: Rosenfield ML, Logan NS, eds.
Optometry: Science, Techniques and Clinical Management.
Edinburgh: Butterworth-Heinemann; 2009:105–120.
93. Chang L, Pan CW, Ohno-Matsui K, et al. Myopia-related
fundus changes in Singapore adults with high myopia. Am J
Ophthalmol. 2013;155:991–999.
94. Evans B. Binocular vision assessment. In: Rosenfield M, NS,
Logan Edwards K, eds. Optometry: Science, Techniques and
Clinical Management. Edinburgh: Butterworth-Heinemann;
2009:241–256.
95. Rosenfield M. Clinical assessment of accommodation. In:
Rosenfield M, Logan NS, eds. Optometry: Science, Tech-
niques and Clinical Management. Edinburgh: Butterworth-
Heinemann; 2009:229–240.
96. Elliot D. Assessment of binocular vision and accommodation.
In: Clinical Procedures in Primary Eye Care. Elsevier
Health Sciences; 2014:147–208.
97. Gifford K, Gifford P, Hendicott P, Schmid K. Binocular visual
function in orthokeratology contact lens wear for myopia.
Invest Ophthalmol Vis Sci. 2017; 58:ARVO E-Abstract 2389.
98. Gwiazda J, Bauer J, Thorn F, Held R. A dynamic relationship
between myopia and blur Driven accommodation in school-
aged children. Vision Res. 1995;35:1299–1304.
99. Gwiazda J, Thorn F, Bauer J, Held R. Myopic children show
insufficient accommodative response to blur. Invest Oph-
thalmol Vis Sci. 1993;34:690–694.
100. Gwiazda JE, Hyman L, Norton TT, et al. Accommodation and
related risk factors associated with myopia progression and
their interaction with treatment in COMET children. Invest
Ophthalmol Vis Sci. 2004;45:2143–2151.
101. Mutti DO, Jones LA, Moeschberger ML, Zadnik K. AC/A ratio,
age, and refractive error in children. Invest Ophthalmol Vis
Sci. 2000;41:2469–2478.
102. Mutti DO, Mitchell GL, Hayes JR, et al. Accommodative lag
before and after the onset of myopia. Invest Ophthalmol Vis
Sci. 2006;47:837–846.
103. Nakatsuka C, Hasebe S, Nonaka F, Ohtsuki H. Accommoda-
tive lag under habitual seeing conditions: comparison
between myopic and emmetropic children. Jpn J Ophthal-
mol. 2005;49:189–194.
104. Cheng D, Woo GC, Drobe B, Schmid KL. Effect of bifocal and
prismatic bifocal spectacles on myopia progression in
children: three-year results of a randomized clinical trial.
JAMA Ophthalmol. 2014;132:258–264.
105. Correction of Myopia Evaluation Trial 2 Study Group for the
Pediatric Eye Disease Investigator Group. Progressive-addition
lenses versus single-vision lenses for slowing progression of
myopia in children with high accommodative lag and near
esophoria. Invest Ophthalmol Vis Sci. 2011;52:2749–2757.
106. Tarrant J, Severson H, Wildsoet CF. Accommodation in
emmetropic and myopic young adults wearing bifocal soft
contact lenses. Ophthalmic Physiol Opt. 2008;28:62–72.
107. Tarrant J, Roorda A, Wildsoet C. Determining the accommo-
dative response from wavefront aberrations. J Vis. 2010;
10(5):4.
108. Kang P, Wildsoet CF. Acute and short-term changes in visual
function with multifocal soft contact lens wear in young
adults. Cont Lens Anterior Eye. 2016;39:133–140.
109. Felipe-Marquez G, Nombela-Palomo M, Cacho I, Nieto-Bona
A. Accommodative changes produced in response to
overnight orthokeratology. Graefe’s Arch Clin Exp Ophthal-
mol. 2015;253:619–626.
110. Brand P. The effect of orthokeratology on accommodative
and convergence function: a clinic based pilot study. Optom
Vis Perf. 2013;1:162–167.
111. McClelland JF, Saunders KJ. The repeatability and validity of
dynamic retinoscopy in assessing the accommodative
response. Ophthalmic Physiol Opt. 2003;23:243–250.
112. McClelland JF, Saunders KJ. Accommodative lag using
dynamic retinoscopy: age norms for school-age children.
Optom Vis Sci. 2004;81:929–933.
113. Harb E, Thorn F, Troilo D. Characteristics of accommodative
behavior during sustained reading in emmetropes and
myopes. Vis Res. 2006;46:2581–2592.
114. Gong CR, Troilo D, Richdale K. Accommodation and phoria
in children wearing multifocal contact lenses. Optom Vis Sci.
2017;94:353–360.
115. Pandian A, Sankaridurg PR, Naduvilath T, et al. Accommo-
dative facility in eyes with and without myopia. Invest
Ophthalmol Vis Sci. 2006;47:4725–4731.
116. Felipe-Marquez G, Nombela-Palomo M, Palomo-Alvarez C,
Cacho I, Nieto-Bona A. Binocular function changes produced
in response to overnight orthokeratology. Graefe’s Arch Clin
Exp Ophthalmol. 2017;255:179–188.
117. Gwiazda J, Grice K, Thorn F. Response AC/A ratios are
elevated in myopic children. Ophthalmic Physiol Opt. 1999;
19:173–179.
118. Arita R, Itoh K, Inoue K, Kuchiba A, Yamaguchi T, Amano S.
Contact lens wear is associated with decrease of meibomian
glands. Ophthalmology. 2009;116:379–384.
119. Mizoguchi T, Arita R, Fukuoka S, Morishige N. Morphology
and function of meibomian glands and other tear film
parameters in junior high school students. Cornea. 2017;36:
922–926.
120. Fonn D. Dryness with contact lenses and dry eye: are they
the same or different? Eye Contact Lens. 2009;35:219.
121. Chalmers R. Overview of factors that affect comfort with
modern soft contact lenses. Cont Lens Anterior Eye. 2014;
37:65–76.
122. Richdale K, Lam DY, Mitchell GL, et al. Geographic and
temporal risk factors for interruptions to soft contact lens
wear in young wearers. Cont Lens Anterior Eye. 2013;36:
253–258.
123. Nichols JJ, Jones L, Nelson JD, et al. The TFOS international
workshop on contact lens discomfort: introduction. Invest
Ophthalmol Vis Sci. 2013;54:TFOS1–TFOS6.
124. Tomlinson A, Bron AJ, Korb DR, et al. The international
workshop on meibomian gland dysfunction: report of the
diagnosis subcommittee. Invest Ophthalmol Vis Sci. 2011;
52:2006–2049.
125. Baudouin C, Labbe´ A, Liang H, Pauly A, Brignole-Baudouin F.
Preservatives in eyedrops: the good, the bad and the ugly.
Prog Retin Eye Res. 2010;29:312–334.
IMI – Clinical Management Guidelines IOVS j Special Issue j Vol. 60 j No. 3 j M199
Downloaded from iovs.arvojournals.org on 05/03/2019
126. Datta S, Baudouin C, Brignole-Baudouin F, Denoyer A,
Cortopassi GA. The eye drop preservative benzalkonium
chloride potently induces mitochondrial dysfunction and
preferentially affects LHON mutant cells. Invest Ophthalmol
Vis Sci. 2017;58:2406–2412.
127. World Health Organization. The Impact of Myopia and High
Myopia. Available at: https://www.who.int/blindness/causes/
MyopiaReportforWeb.pdf. Accessed August 10, 2018.
128. Wu Y, Li H, Tang Y, Yan X. Morphological evaluation of
meibomian glands in children and adolescents using
noncontact infrared meibography. J Pediatr Ophthalmol
Strabismus. 2017;54:78–83.
129. Cardona G, Garcia C, Seres C, Vilaseca M, Gispets J. Blink
rate, blink amplitude, and tear film integrity during dynamic
visual display terminal tasks. Curr Eye Res. 2011;36:190–
197.
130. Moon JH, Lee MY, Moon NJ. Association between video
display terminal use and dry eye disease in school children. J
Pediatr Ophthalmol Strabismus. 2014;51:87–92.
131. Moon JH, Kim KW, Moon NJ. Smartphone use is a risk factor
for pediatric dry eye disease according to region and age: a
case control study. BMC Ophthalmol. 2016;16:188.
132. Benedetto S, Drai-Zerbib V, Pedrotti M, Tissier G, Baccino T.
E-readers and visual fatigue. PLoS One. 2013;8:e83676.
133. Craig JP, Nelson JD, Azar DT, et al. TFOS DEWS II Report
Executive Summary. Ocul Surf. 2017;15:802–812.
134. Hoogerheide J, Rempt F, Hoogenboom WP. Acquired myopia
in young pilots. Ophthalmologica. 1971;163:209–215.
135. Chen X, Sankaridurg P, Donovan L, et al. Characteristics of
peripheral refractive errors of myopic and non-myopic
Chinese eyes. Vis Res. 2010;50:31–35.
136. Sng CC, Lin XY, Gazzard G, et al. Peripheral refraction and
refractive error in singapore chinese children. Invest
Ophthalmol Vis Sci. 2011;52:1181–1190.
137. Ehsaei A, Mallen EA, Chisholm CM, Pacey IE. Cross-sectional
sample of peripheral refraction in four meridians in myopes
and emmetropes. Invest Ophthalmol Vis Sci. 2011;52:7574–
7585.
138. Atchison DA, Li SM, Li H, et al. Relative peripheral hyperopia
does not predict development and progression of myopia in
children. Invest Ophthalmol Vis Sci. 2015;56:6162–6170.
139. Lee TT, Cho P. Relative peripheral refraction in children:
twelve-month changes in eyes with different ametropias.
Ophthalmic Physiol Opt. 2013;33:283–293.
140. Kang P, Swarbrick H. Peripheral refraction in myopic
children wearing orthokeratology and gas-permeable lenses.
Optom Vis Sci. 2011;88:476–482.
141. Queiro´s A, Gonza´lez-Me´ijome JM, Jorge J, Villa-Collar C,
Gutie´rrez AR. Peripheral refraction in myopic patients after
orthokeratology. Optom Vis Sci. 2010;87:323–329.
142. Gifford P, Gifford K, Hendicott P, Schmid K. Relative
peripheral refraction and binocular vision changes in
myopic orthokeratology. Invest Ophthalmol Vis Sci. 2017;
58 :ARVO E-Abstract 2390.
143. Hiraoka T, Kotsuka J, Kakita T, Okamoto F, Oshika T.
Relationship between higher-order wavefront aberrations
and natural progression of myopia in schoolchildren. Sci
Rep. 2017;7:7876.
144. Santodomingo-Rubido J, Villa-Collar C, Gilmartin B, Gutier-
rez-Ortega R, Suzaki A. The effects of entrance pupil
centration and coma aberrations on myopic progression
following orthokeratology. Clin Exp Optom. 2015;98:534–
540.
145. Chen Z, Niu L, Xue F, et al. Impact of pupil diameter on axial
growth in orthokeratology. Optom Vis Sci. 2012;89:1636–
1640.
146. Read SA, Alonso-Caneiro D, Vincent SJ, Collins MJ. Longitu-
dinal changes in choroidal thickness and eye growth in
childhood. Invest Ophthalmol Vis Sci. 2015;56:3103–3112.
147. Wang D, Chun RK, Liu M, et al. Optical defocus rapidly
changes choroidal thickness in schoolchildren. PLoS One.
2016;11:e0161535.
148. Li Z, Cui D, Hu Y, Ao S, Zeng J, Yang X. Choroidal thickness
and axial length changes in myopic children treated with
orthokeratology. Cont Lens Anterior Eye. 2017;40:417–423.
149. Dirani M, Tong L, Gazzard G, et al. Outdoor activity and
myopia in Singapore teenage children. Br J Ophthalmol.
2009;93:997–1000.
150. Onal S, Toker E, Akingol Z, et al. Refractive errors of medical
students in Turkey: one year follow-up of refraction and
biometry. Optom Vis Sci. 2007;84:175–180.
151. Parssinen O, Lyyra AL. Myopia and myopic progression
among schoolchildren: a three-year follow-up study. Invest
Ophthalmol Vis Sci. 1993;34:2794–2802.
152. Rose KA, Morgan IG, Ip J, et al. Outdoor activity reduces the
prevalence of myopia in children. Ophthalmology. 2008;
115:1279–1285.
153. Guo Y, Liu LJ, Xu L, et al. Outdoor activity and myopia among
primary students in rural and urban regions of Beijing.
Ophthalmology. 2013;120:277–283.
154. Alvarez AA, Wildsoet CF. Quantifying light exposure patterns
in young adult students. J Mod Opt. 2013;60:1200–1208.
155. Dharani R, Lee CF, Theng ZX, et al. Comparison of
measurements of time outdoors and light levels as risk
factors for myopia in young Singapore children. Eye. 2012;
26:911–918.
156. Schmid KL, Leyden K, Chiu YH, et al. Assessment of daily
light and ultraviolet exposure in young adults. Optom Vis
Sci. 2013;90:148–155.
157. Ostrin LA. Objectively measured light exposure in emme-
tropic and myopic adults. Optom Vis Sci. 2017;94:229–238.
158. Scheuermaier K, Laffan AM, Duffy JF. Light exposure
patterns in healthy older and young adults. J Biol Rhythms.
2010;25:113–122.
159. Dharani R, Lee CF, Finkelstein EA, Saw SM. Response to
Mahroo et al. Eye. 2013;27:991.
160. Mahroo OA, Gavin EA, Williams KM, De Smit E, Hammond
CJ, Morrison DA. Potential effect of ‘cut-off intensity’ on
correlation between light meter measurements and time
outdoors. Eye. 2013;27:990–991.
161. Read SA, Collins MJ, Vincent SJ. Light exposure and eye
growth in childhood. Invest Ophthalmol Vis Sci. 2015;56:
6779–6787.
162. Loh KL, Lu Q, Tan D, Chia A. Risk factors for progressive
myopia in the atropine therapy for myopia study. Am J
Ophthalmol. 2015;159:945–949.
163. Hsu CC, Huang N, Lin PY, et al. Risk factors for myopia
progression in second-grade primary school children in
Taipei: a population-based cohort study. Br J Ophthalmol.
2017;101:1611–1617.
164. Saw SM, Nieto FJ, Katz J, Schein OD, Levy B, Chew SJ. Factors
related to the progression of myopia in singaporean
children. Optom Vis Sci. 2000;77:549–554.
165. Gwiazda J, Deng L, Manny R, Norton TT. Seasonal variations
in the progression of myopia in children enrolled in the
correction of myopia evaluation trial. Invest Ophthalmol Vis
Sci. 2014;55:752–758.
166. Williams KM, Hysi PG, Nag A, Yonova Doing E, Venturini C,
Hammond CJ. Age of myopia onset in a British population-
based twin cohort. Ophthalmic Physiol Opt 2013;33:339–345.
167. Iribarren R, Cortinez MF, Chiappe JP. Age of first distance
prescription and final myopic refractive error. Ophthalmic
Epidemiol. 2009;16:84–89.
IMI – Clinical Management Guidelines IOVS j Special Issue j Vol. 60 j No. 3 j M200
Downloaded from iovs.arvojournals.org on 05/03/2019
168. Richdale K, Berntsen DA, Mack CJ, Merchea MM, Barr JT.
Visual acuity with spherical and toric soft contact lenses in
low- to moderate-astigmatic eyes. Optom Vis Sci. 2007;84:
969–975.
169. Swarbrick HA. Orthokeratology review and update. Clin Exp
Optom. 2006;89:124–143.
170. Chen C, Cheung SW, Cho P. Myopia control using toric
orthokeratology (TO-SEE Study). Invest Ophthalmol Vis Sci.
2013;54:6510–6517.
171. Charm J, Cho P. High myopia-partial reduction ortho-k: a 2-
year randomized study. Optom Vis Sci. 2013;90:530–539.
172. Cho P, Cheung SW. Retardation of Myopia in Orthokeratol-
ogy (ROMIO) Study: a 2-year randomized clinical trial. Invest
Ophthalmol Vis Sci. 2012;53:7077–7085.
173. Hiraoka T, Kakita T, Okamoto F, Takahashi H, Oshika T. Long-
term effect of overnight orthokeratology on axial length
elongation in childhood myopia: a 5-year follow-up study.
Invest Ophthalmol Vis Sci. 2012;53:3913–3919.
174. Kakita T, Hiraoka T, Oshika T. Influence of overnight
orthokeratology on axial elongation in childhood myopia.
Invest Ophthalmol Vis Sci. 2011;52:2170–2174.
175. Cho P, Cheung SW, Edwards M. The longitudinal orthokera-
tology research in children (LORIC) in Hong Kong: a pilot
study on refractive changes and myopic control. Curr Eye
Res. 2005;30:71–80.
176. Cheng D, Woo GC, Drobe B, Schmid KL. Effect of bifocal and
prismatic bifocal spectacles on myopia progression in
children: three-year results of a randomized clinical trial.
JAMA Ophthalmol. 2014;132:258–264.
177. Zhu M, Feng H, Zhu J, Qu X. The impact of amplitude of
accommodation on controlling the development of myopia
in orthokeratology. Zhonghua Yan Ke Za Zhi. 2014;50:14–
19.
178. Li SM, Wu SS, Kang MT, et al. Atropine slows myopia
progression more in Asian than white children by meta-
analysis. Optom Vis Sci. 2014;91:342–350.
179. Wolffsohn JS, Calossi A, Cho P, et al. Global trends in myopia
management attitudes and strategies in clinical practice.
Cont Lens Anterior Eye. 2016;39:106–116.
180. Walline JJ, Greiner KL, McVey ME, Jones-Jordan LA.
Multifocal contact lens myopia control. Optom Vis Sci.
2013;90:1207–1214.
181. Sankaridurg P, Holden B, Smith E III, et al. Decrease in rate of
myopia progression with a contact lens designed to reduce
relative peripheral hyperopia: one-year results. Invest
Ophthalmol Vis Sci. 2011;52:9362–9367.
182. Lam CS, Tang WC, Tse DY, Tang YY, To CH. Defocus
Incorporated Soft Contact (DISC) lens slows myopia
progression in Hong Kong Chinese schoolchildren: a 2-year
randomised clinical trial. Br J Ophthalmol. 2014;98:40–45.
183. Fujikado T, Ninomiya S, Kobayashi T, Suzaki A, Nakada M,
Nishida K. Effect of low-addition soft contact lenses with
decentered optical design on myopia progression in
children: a pilot study. Clin Ophthalmol. 2014;8:1947–1956.
184. Cheng X, Xu J, Chehab K, Exford J, Brennan N. Soft contact
lenses with positive spherical aberration for myopia control.
Optom Vis Sci. 2016;93:353–366.
185. Paune J, Morales H, Armengol J, Quevedo L, Faria-Ribeiro M,
Gonzalez-Meijome JM. Myopia control with a novel periph-
eral gradient soft lens and orthokeratology: a 2-year clinical
trial. Biomed Res Int. 2015;2015:507572.
186. Paune J, Queiros A, Quevedo L, Neves H, Lopes-Ferreira D,
Gonzalez-Meijome JM. Peripheral myopization and visual
performance with experimental rigid gas permeable and soft
contact lens design. Cont Lens Anterior Eye. 2014;37:455–
460.
187. Gifford P, Gifford KL. The future of myopia control contact
lenses. Optom Vis Sci. 2016;93:336–343.
188. Sankaridurg P. Contact lenses to slow progression of myopia.
Clin Exp Optom. 2017;100:432–437.
189. Berntsen DA, Kramer CE. Peripheral defocus with spherical
and multifocal soft contact lenses. Optom Vis Sci. 2013;90:
1215–1224.
190. Ticak A, Walline JJ. Peripheral optics with bifocal soft and
corneal reshaping contact lenses. Optom Vis Sci. 2013;90:3–
8.
191. Kang P, Fan Y, Oh K, Trac K, Zhang F, Swarbrick HA. The
effect of multifocal soft contact lenses on peripheral
refraction. Optom Vis Sci. 2013;90:658–666.
192. Lopes-Ferreira D, Ribeiro C, Maia R, et al. Peripheral
myopization using a dominant design multifocal contact
lens. J Optom. 2011;4:14–32.
193. Smith EL III. Optical treatment strategies to slow myopia
progression: effects of the visual extent of the optical
treatment zone. Exp Eye Res. 2013;114:77–88.
194. Walline JJ, Gaume Giannoni A, Sinnott LT, et al. A
randomized trial of soft multifocal contact lenses for myopia
control: baseline data and methods. Optom Vis Sci. 2017;94:
856–866.
195. Kang P, McAlinden C, Wildsoet CF. Effects of multifocal soft
contact lenses used to slow myopia progression on quality of
vision in young adults. Acta Ophthalmol. 2017;95:e43–e53.
196. Bickle K, Walline J. Bifocal Lenses in Nearsighted Kids
(BLINK) study. Optom Vis Sci. 2013;90 . Abstract 130789.
197. Schulle KL, Berntsen DA, Sinnott LT, et al. Visual acuity and
over-refraction in myopic children fitted with soft multifocal
contact lenses. Optom Vis Sci. 2018;95:292–298.
198. Chung K, Mohidin N, O’Leary DJ. Undercorrection of
myopia enhances rather than inhibits myopia progression.
Vision Res. 2002;42:2555–2559.
199. Adler D, Millodot M. The possible effect of undercorrection
on myopic progression in children. Clin Exp Optom. 2006;
89:315–321.
200. Sun YY, Li SM, Li SY, et al. Effect of uncorrection versus full
correction on myopia progression in 12-year-old children.
Graefe’s Arch Clin Exp Ophthalmol. 2017;255:189–195.
201. Gwiazda J, Grice K, Held R, Thorn F, Bauer J. Insufficient
accommodation and near esophoria: precursors or concom-
itants of juvenile-onset myopia? In: Tokoro T, ed. Myopia
Updates. Tokyo: Springer; 1998;92–97.
202. Edwards MH, Li RW-H, Lam CS-Y, Lew JK-F, Yu BS-Y. The
Hong Kong progressive lens myopia control study: study
design and main findings. Invest Ophthalmol Vis Sci. 2002;
43:2852–2858.
203. Berntsen DA, Mutti DO, Zadnik K. Study of Theories about
Myopia Progression (STAMP) design and baseline data.
Optom Vis Sci. 2010;87:823–832
204. Hyman L, Gwiazda J, Marsh-Tootle WL, Norton TT, Hussein
M. The Correction of Myopia Evaluation Trial (COMET):
design and general baseline characteristics. Control Clin
Trials. 2001;22:573–592.
205. Scheiman M, Wick B. Clinical Management of Binocular
Vision: Heterophoric, Accommodative and Eye Movement
Disorders. Philadephia: Lippincott Williams & Wilkins;
1994.
206. Sankaridurg P, Donovan L, Varnas S, et al. Spectacle lenses
designed to reduce progression of myopia: 12-month results.
Optom Vis Sci. 2010;87:631–641.
207. Lam CS-Y, Tang WC, Lee RP, Chun RK, To CH. Myopia
control with multi-segment myopic defocus (MSMD) spec-
tacle lens: a randomised clinical trial. Ophthal Physiol Opt.
2017;37:O017.
IMI – Clinical Management Guidelines IOVS j Special Issue j Vol. 60 j No. 3 j M201
Downloaded from iovs.arvojournals.org on 05/03/2019
208. Guggenheim JA, Northstone K, McMahon G, et al. Time
outdoors and physical activity as predictors of incident
myopia in childhood: a prospective cohort study. Invest
Ophthalmol Vis Sci. 2012;53:2856–2865.
209. He M, Xiang F, Zeng Y, et al. Effect of time spent outdoors at
school on the development of myopia among children in
China: a randomized clinical trial. JAMA Ophthalmol. 2015;
314:1142–1148.
210. Jones-Jordan LA, Sinnott LT, Cotter SA, et al. Time outdoors,
visual activity, and myopia progression in juvenile-onset
myopes. Invest Ophthalmol Vis Sci. 2012;53:7169–7175.
211. Norton TT, Amedo AO, Siegwart JT Jr. Darkness causes
myopia in visually experienced tree shrews. Invest Oph-
thalmol Vis Sci. 2006;47:4700–4707.
212. Ashby R, Ohlendorf A, Schaeffel F. The effect of ambient
illuminance on the development of deprivation myopia in
chicks. Invest Ophthalmol Vis Sci. 2009;50:5348–5354.
213. Smith EL III, Hung LF, Huang J. Protective effects of high
ambient lighting on the development of form Deprivation
myopia in rhesus monkeys. Invest Ophthalmol Vis Sci. 2012;
53:421–428.
214. Saw SM, Katz J, Schein OD, Chew SJ, Chan TK. Epidemiology
of myopia. Epidemiol Rev. 1996;18:175–187.
215. Edwards MH. Do variations in normal nutrition play a role in
the development of myopia? Optom Vis Sci. 1996;73:638–
643.
216. Gardiner PA. The diet of growing myopes. Trans Ophthal-
mol Soc UK. 1956;76:171–180.
217. Lim LS, Gazzard G, Low YL, et al. Dietary factors, myopia,
and axial dimensions in children. Ophthalmology. 2010;117:
993–997.
218. Trier K, Munk Ribel-Madsen S, Cui D, Brogger Christensen S.
Systemic 7-methylxanthine in retarding axial eye growth and
myopia progression: a 36-month pilot study. J Ocular Biol
Dis Informat. 2008;1:85–93.
219. Hong T, Flood V, Rochtchina E, Mitchell P, Russell J, Wang JJ.
Adherence to dietary guidelines and the 10-year cumulative
incidence of visual impairment: the Blue Mountains Eye
Study. Am J Ophthalmol. 2014;158:302–308.
220. Wu YT, Willcox MD, Stapleton F. The effect of contact lens
hygiene behavior on lens case contamination. Optom Vis
Sci. 2015;92:167–174.
221. Lim CH, Carnt NA, Farook M, et al. Risk factors for contact
lens-related microbial keratitis in Singapore. Eye. 2016;30:
447–455.
222. Zimmerman AB, Richdale K, Mitchell GL, et al. Water
exposure is a common risk behavior among soft and gas-
permeable contact lens wearers. Cornea. 2017;36:995–
1001.
223. Carnt N, Stapleton F. Strategies for the prevention of contact
lens-related Acanthamoeba keratitis: a review. Ophthalmic
Physiol Opt. 2016;36:77–92.
224. Morgan PB, Efron N, Brennan NA, Hill EA, Raynor MK, Tullo
AB. Risk factors for the development of corneal infiltrative
events associated with contact lens wear. Invest Ophthal-
mol Vis Sci. 2005;46:3136–3143.
225. Richdale K, Lam DY, Wagner H, et al. Case-control pilot study
of soft contact lens wearers with corneal infiltrative events
and healthy controls. Invest Ophthalmol Vis Sci. 2016;57:
47–55.
226. Sorbara L, Zimmerman AB, Mitchell GL, et al. Multicenter
testing of a risk assessment survey for soft contact lens
wearers with adverse events: a contact lens assessment in
youth study. Eye Cont Lens. 2016.
227. Wu YT, Willcox M, Zhu H, Stapleton F. Contact lens hygiene
compliance and lens case contamination: A review. Cont
Lens Anterior Eye. 2015;38:307–316.
228. Stapleton F, Edwards K, Keay L, et al. Risk factors for
moderate and severe microbial keratitis in daily wear contact
lens users. Ophthalmology. 2012;119:1516–1521.
229. Schein OD, Glynn RJ, Poggio EC, Seddon JM, Kenyon KR.
The relative risk of ulcerative keratitis among users of daily-
wear and extended-wear soft contact lenses. A case-control
study. Microbial Keratitis Study Group. New Engl J Med.
1989;321:773–778.
230. Feghhi M, Mahmoudabadi AZ, Mehdinejad M. Evaluation of
fungal and bacterial contaminations of patient-used ocular
drops. Med Mycol. 2008;46:17–21.
231. Chia A, Lu QS, Tan D. Five-year clinical trial on atropine for
the treatment of myopia 2: myopia control with atropine
0.01% eyedrops. Ophthalmology. 2016;123:391–399.
232. Berntsen DA, Schulle KL, Sinnott LT, Bickle KM, Group TBS.
Visual acuity and over-refraction in myopic children fitted
with soft multifocal contact lenses in the BLINK Study.
Invest Ophthalmol Vis Sci. 2017;58:ARVO E-Abstract 3052.
233. Wong HB, Machin D, Tan SB, Wong TY, Saw SM. Ocular
component growth curves among Singaporean children
with different refractive error status. Invest Ophthalmol Vis
Sci. 2010;51:1341–1347.
234. French AN, Morgan IG, Burlutsky G, Mitchell P, Rose KA.
Prevalence and 5- to 6-year incidence and progression of
myopia and hyperopia in Australian schoolchildren. Oph-
thalmology. 2013;120:1482–1491.
235. Saw SM, Tong L, Chua WH, et al. Incidence and progression
of myopia in Singaporean school children. Invest Ophthal-
mol Vis Sci. 2005;46:51–57.
236. Aller TA. Clinical management of progressive myopia. Eye
2014;28:147–153.
237. Pineles SL, Kraker RT, VanderVeen DK, et al. Atropine for the
prevention of myopia progression in children: a report by
the American Academy of Ophthalmology. Ophthalmol.
2017;124:1857–1866.
238. Santodomingo-Rubido J, Villa-Collar C, Gilmartin B, Gutier-
rez-Ortega R, Sugimoto K. Long-term efficacy of orthokera-
tology contact lens wear in controlling the progression of
childhood myopia. Curr Eye Res. 2017;42:713–720.
239. Fulk GW, Cyert LA, Parker DE. A randomized trial of the
effect of single-vision vs. bifocal lenses on myopia progres-
sion in children with esophoria. Optom Vis Sci. 2000;77:
395–401.
240. Jones LA, Mitchell GL, Mutti DO, Hayes JR, Moeschberger
ML, Zadnik K. Comparison of ocular component growth
curves among refractive error groups in children. Invest
Ophthalmol Vis Sci. 2005;46:2317–2327.
241. Kinoshita N, Konno Y, Hamada N, Kakehashi A. Suppressive
effect of combined treatment of orthokeratology and 0.01%
atropine instillation on axial length elongation in childhood
myopia. Invest Ophthalmol Vis Sci. 2017;58:ARVO E-
Abstract 2386.
242. Verzhanskaya TY, Tarutta EP. Stabilizing effectiveness of
orthokeratology and long-term minute-concentration atro-
pine therapy in myopia [in Russian]. Vestn Oftalmol. 2017;
133:43–48.
243. Polling JR, Kok RG, Tideman JW, Meskat B, Klaver CC.
Effectiveness study of atropine for progressive myopia in
Europeans. Eye (Lond). 2016;30:998–1004.
244. Cho P, Cheung SW. Discontinuation of orthokeratology on
eyeball elongation (DOEE). Cont Lens Anterior Eye. 2017;
40:82–87.
245. Goss DA, Winkler RL. Progression of myopia in youth: age of
cessation. Am J Optom Physiol Opt. 1983;60:651–658.
246. Comet Group. Myopia stabilization and associated factors
among participants in the Correction of Myopia Evaluation
Trial (COMET). Invest Ophthalmol Vis Sci. 2013;54:7871–
7884.
IMI – Clinical Management Guidelines IOVS j Special Issue j Vol. 60 j No. 3 j M202
Downloaded from iovs.arvojournals.org on 05/03/2019
247. Rahi JS, Cumberland PM, Peckham CS. Myopia over the
lifecourse: prevalence and early life influences in the 1958
British birth cohort. Ophthalmology. 2011;118:797–804.
248. Zadnik K, Mutti DO. Refractive error changes in law
students. Am J Optom Physiol Opt. 1987;64:558–561.
249. Kinge B, Midelfart A. Refractive errors among engineering
students in Norway. Ophthalmic Epidemiol. 1994;1:5–13.
250. Lv L, Zhang Z. Pattern of myopia progression in Chinese
medical students: a two-year follow-up study. Graefes Arch
Clin Exp Ophthalmol. 2013;251:163–168.
251. Lim R, Mitchell P, Cumming RG. Refractive associations with
cataract: the Blue Mountains Eye Study. Invest Ophthalmol
Vis Sci. 1999;40:3021–3026.
252. Younan C, Mitchell P, Cumming RG, Rochtchina E, Wang JJ.
Myopia and incident cataract and cataract surgery: the Blue
Mountains eye study. Invest Ophthalmol Vis Sci. 2002;43:
3625–3632.
253. Ponte F, Giuffre G, Giammanco R, Dardanoni G. Risk factors
of ocular hypertension and glaucoma. The Casteldaccia Eye
Study. Adv Ophthalmol. 1994;85:203–210.
254. Wong TY, Klein BEK, Klein R, Knudtson M, Lee KE.
Refractive errors, intraocular pressure, and glaucoma in a
white population11The authors have no proprietary interest
in the products or devices mentioned herein. Ophthalmol-
ogy. 2003;110:211–217.
255. Pierro L, Camesasca FI, Mischi M, Brancato R. Peripheral
retinal changes and axial myopia. Retina. 1992;12:12–17.
256. Yura T. The relationship between the types of axial
elongation and the prevalence of lattice degeneration of
the retina. Acta Ophthalmol Scand. 1998;76:90–95.
257. Rosner M, Treister G, Belkin M. Epidemiology of retinal
detachment in childhood and adolescence. J Pediatr
Ophthalmol Strabismus. 1987;24:42–44.
258. Logan NS, Gilmartin B, Marr JE, Stevenson MR, Ainsworth JR.
Community-based study of the association of high myopia in
children with ocular and systemic disease. Optom Vis Sci.
2004;81:11–13.
259. Bansal AS, Hubbard GB III. Peripheral retinal findings in
highly myopic children < or¼10 years of age. Retina. 2010;
30:S15–S19.
260. Cheng SC, Lam CS, Yap MK. Prevalence of myopia-related
retinal changes among 12-18 year old Hong Kong Chinese
high myopes. Ophthalmic Physiol Opt. 2013;33:652–660.
261. Smith EL III, Hung L-F, Huang J, Arumugam B. Effects of local
myopic defocus on refractive development in monkeys.
Optom Vis Sci. 2013;90:1176–1186.
262. Berntsen DA, Kramer CE. Peripheral defocus with spherical
and multifocal soft contact lenses. Optom Vis Sci. 2013;90:
1215–1224.
263. Kang P, Fan Y, Oh K, Trac K, Zhang F, Swarbrick HA. The
effect of multifocal soft contact lenses on peripheral
refraction. Optom Vis Sci. 2013;90:658–666.
264. Marcotte-Collard R, Simard P, Michaud L. Analysis of two
orthokeratology lens designs and comparison of their
optical effects on the cornea. Eye Contact Lens. 2018;44:
322–329.
265. Trier K, Munk Ribel-Madsen S, Cui D, Brøgger Christensen S.
Systemic 7-methylxanthine in retarding axial eye growth and
myopia progression: a 36-month pilot study. J Ocul Biol Dis
Infor. 2008;1:85–93.
266. Trier K, Olsen EB, Kobayashi T, Ribel-Madsen SM. Biochemical
and ultrastructural changes in rabbit sclera after treatment with
7-methylxanthine, theobromine, acetazolamide, or L-ornithine.
Br J Ophthalmol. 1999;83:1370–1375.
267. Cui D, Trier K, Zeng J, et al. Effects of 7-methylxanthine on
the sclera in form deprivation myopia in guinea pigs. Acta
Ophthalmol. 2011;89:328–334.
268. Hung LF, Arumugam B, Ostrin L, et al. The adenosine
receptor antagonist, 7-methylxanthine, alters emmetropizing
responses in infant macaques. Invest Ophthalmol Vis Sci.
2018;59:472–486.
269. Arumugam B, Hung LF, Jong M, Ostrin LA, Smith EL III.
Topically applied caffeine, a non-selective adenosine antag-
onist, alters emmetropizing responses in infant monkeys.
Ophthal Physiol Opt. 2017; 37:O025.
270. Hu H, Zhao G, Wu R, Zhong H, Fang M, Deng H. Axial
length/corneal radius of curvature ratio assessment of
posterior sclera reinforcement for pathologic myopia.
Ophthalmologica. 2018;239:128–132.
271. Wollensak G, Iomdina E, Dittert DD, Salamatina O, Stolten-
burg G. Cross-linking of scleral collagen in the rabbit using
riboflavin and UVA. Acta Ophthalmol Scand. 2005;83:477–
482.
272. Zhang M, Zou Y, Zhang F, Zhang X, Wang M. Efficacy of blue-
light cross-linking on human scleral reinforcement. Optom
Vis Sci. 2015;92:873–878.
273. Garcia MB, Jha AK, Healy KE, Wildsoet CF. A bioengineering
approach to myopia control tested in a guinea pig model.
Invest Ophthalmol Vis Sci. 2017;58:1875–1886.
274. Ward B, Tarutta EP, Mayer MJ. The efficacy and safety of
posterior pole buckles in the control of progressive high
myopia. Eye. 2009;23:2169–2174.
275. Ward B. Degenerative myopia: myopic macular schisis and
the posterior pole buckle. Retina. 2013;33:224–231.
276. Nickla DL, Jordan K, Yang J, Totonelly K. Brief hyperopic
defocus or form deprivation have varying effects on eye
growth and ocular rhythms depending on the time-of day of
exposure. Exp Eye Res. 2017;161:132–142.
277. Ayaki M, Torii H, Tsubota K, Negishi K. Decreased sleep
quality in high myopia children. Sci Rep. 2016;6:33902.
278. Abbott KS, Queener HM, Ostrin LA. The ipRGC Driven pupil
response with light exposure, refractive error, and sleep.
Optom Vis Sci. 2018;95:323–331.
279. Jee D, Morgan IG, Kim EC. Inverse relationship between
sleep duration and myopia. Acta Ophthalmol. 2016;94:
e204–e210.
280. Kearney S, O’Donoghue L, Pourshahidi LK, Cobice D,
Saunders KJ. Myopes have significantly higher serum
melatonin concentrations than non-myopes. Ophthalmic
Physiol Opt. 2017;37:557–567.
281. Rucker F, Britton S, Spatcher M, Hanowsky S. Blue light
protects against temporal frequency sensitive refractive
changes. Invest Ophthalmol Vis Sci. 2015;56:6121–6131.
IMI – Clinical Management Guidelines IOVS j Special Issue j Vol. 60 j No. 3 j M203
Downloaded from iovs.arvojournals.org on 05/03/2019
